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1. INTRODUCTION
Carbonic anhydrases (CAs, EC 4.2.1.1) are ubiquitous metallo-
enzymes, present throughout most living organisms and
encoded by five evolutionarily unrelated gene families: the α-,
β-, γ-, δ-, and ζ-CAs.1−6 The α- β- and δ-CAs contain a Zn(II)
ion at the active site, the γ-CAs are probably Fe(II) enzymes
(but they are active also with Zn(II) or Co(II) ions), while the
metal ion is usually replaced by cadmium in the ζ-CAs.5,7−9
All these enzymes catalyze the reversible hydration of carbon
dioxide to bicarbonate ion and proton (CO2 + H2O⇆ HCO3
−
+ H+), following a two step catalytic mechanism.2 In the
hydration direction, the first step is the nucleophilic attack of a
Zn2+-bound hydroxide ion on CO2 with consequent formation
of HCO3
−, which is then displaced from the active site by a
water molecule (eq 1). The second step, which is rate limiting,
regenerates the catalytically active Zn2+-bound hydroxide ion
through a proton transfer reaction from the Zn2+-bound water
molecule to an exogenous proton acceptor or to an active site
residue, generically represented by B in eq 2.
+
⇆
⇆ +
+ −
+ −
+ −



EZn OH CO
EZn HCO
EZn H O HCO
2
2
2
3
2
2 3 (1)
+ ⇆ ++ + − + EZn H O B EZn OH BH2 2 2 (2)
All human CAs (hCAs) belong to the α-class; up to now,
fifteen isozymes have been identified, which differ by molecular
features, oligomeric arrangement, cellular localization, distribu-
tion in organs and tissues, expression levels, kinetic properties
and response to different classes of inhibitors (Table 1).2,10
Twelve isoforms (CA I−IV, VA−VB, VI−VII, IX, and XII−
XIV) show a variable degree of enzymatic activity, whereas
three isoforms (VIII, X, and XI), the so-called CA-related
proteins (CARPs), are devoid of any catalytic activity (Table
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1).2,5,11 Several studies demonstrated important roles of CAs in
a variety of physiological processes, and showed that abnormal
levels or activities of these enzymes have been often associated
with different human diseases.2,3 Consequently, in recent years
CA isozymes have become an interesting target for the design
of inhibitors or activators with biomedical applications.2,12−18
CA activators may have pharmacological applications in
pathologies in which learning and memory are impaired, such
as Alzheimer’s disease or aging.19 On the other hand, CA
inhibitors (CAIs) have been originally used as diuretics,
antiglaucoma agents, antiepileptics, and in the management of
altitude sickness,2 while novel generation compounds are
undergoing clinical investigation as antiobesity, and antitumor
drugs/diagnostic tools.2,20−26
Table 2 shows a brief presentation of the various hCA
isoforms as drug targets/off-targets. Indeed, some of them
(such as CA I and II) are ubiquitous and may be both targets
for some diseases and off-targets, and in this case their
inhibition should be avoided (e.g., CA IX and XII in tumors
should be inhibited by compounds, which do not affect the
activity of CA I, II, VA, and VB).27 Specifically CA I is found in
many tissues, but a seminal study from Feeener’s group28
demonstrated that this enzyme is involved in retinal and
cerebral edema, and its inhibition may be a valuable tool for
fighting these conditions. CA II is involved in several diseases,
such as glaucoma, edema, epilepsy, and probably altitude
sickness.26,29−33 CA III is involved in the oxidative stress,
characterizing a lot of inflammatory diseases. It is not yet
understood whether this feature is due to the CO2 hydration
activity of CA III (which is quite low), or to other enzyme
properties, such as a different enzymatic activity or the presence
of Cys residues on its surface, responsible for the antioxidant
effects of this protein.34−36 CA IV is surely a drug target for
several pathologies, including glaucoma (together with CA II
and XII), retinitis pigmentosa and stroke.37−40 The mitochon-
drial isoforms CA VA and VB are targets for obtaining
antiobesity agents,20−22,41 whereas CA VI is implicated in
cariogenesis.42,43 CA VII has been noted for its contributions to
epileptiform activity together with CA II and XIV.26,31,44 CA
VIII was demonstrated to be involved in neurodegenerative
diseases, as the CA8 gene has been associated with ataxia, mild
mental retardation and quadrupedal gait in humans and with
lifelong gait disorder in mice, suggesting an important role for
CA VIII in the brain.45 It was also found to be involved in the
development of colorectal and lung cancers in humans, and its
overexpression has been observed in several other cancers.45,46
However, nothing is known regarding the involvement of the
remaining two acatalytic isoforms, CA X and XI, in human
pathologies or what is the physiological function of these two
proteins conserved all over the phylogenetic tree in
vertebrates.45 CA IX and XII are well-established anticancer
Table 1. Organ/Tissue Distribution, Subcellular Localization, CO2 Hydrase Activity, and Affinity for Sulfonamides of the 15
Human α-CA Isozymes2,10
organ/tissue distribution subcellular localization
catalytic activity (CO2
hydration)
affinity for
sulfonamides
CA I erythrocytes, gastrointestinal tract, eye cytosol low medium
CA II erythrocytes, eye, gastrointestinal tract, bone osteoclasts, kidney, lung,
testis, brain
cytosol high very high
CA III skeletal muscle, adipocytes cytosol very low very low
CA IV kidney, lung, pancreas, brain capillaries, colon, heart muscle, eye membrane-bound medium high
CA VA liver mitochondria low high
CA VB heart and skeletal muscle, pancreas, kidney, spinal cord, gastrointestinal
tract
mitochondria high high
CA VI salivary and mammary glands secreted into saliva and
milk
low very high
CA VII central nervous system cytosol high very high
CA VIII central nervous system cytosol acatalytic NDa
CA IX tumours, gastrointestinal mucosa transmembrane high high
CA X central nervous system cytosol acatalytic NDa
CA XI central nervous system cytosol acatalytic NDa
CA XII kidney, intestine, reproductive epithelia, eye, tumors transmembrane low very high
CA XIII kidney, brain, lung, gut, reproductive tract cytosol low high
CA XIV kidney, brain, liver, eye transmembrane low high
aND = not determined.
Table 2. hCA Isoforms as Drug Targets/Offtargets in
Various Diseasesa
isoform
disease in which is
involved
possible offtargets among other
hCAs
CA I retinal/cerebral edema28 unknown
CA II glaucoma29 hCA I
edema30 unknown
epilepsy26,31 unknown
altitude sickness32,33 unknown
CA III oxidative stress34−36 unknown
CA IV glaucoma37 hCA I
retinitis pigmentosa38,39 unknown
stroke40 unknown
CA VA/VB obesity20−22,41 hCA I, hCA II
CA VI cariogenesis42,43 hCA II
CA VII epilepsy26,31,44 unknown
CA VIII neurodegeneration45 unknown
cancer45 unknown
CA IX cancer24,27,47 hCA I, hCA II
CA XII cancer24,47,48 hCA I, hCA II
glaucoma49 unknown
CA XIII sterility50 unknown
CA XIV epilepsy26,51 unknown
retinopathy52 unknown
aNo data are available in the literature on CA X and XI involvement in
diseases.
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drug targets. CA IX is a marker of disease progression in many
types of hypoxic tumors, and recently its inhibition has been
shown to be associated with a significant inhibition of the
growth of both primary tumors and metastases. Furthermore,
CAIs targeting this isoform can also be used for imaging of
hypoxic tumors.24,27,47 CA XII is less investigated but basically
it is also an antitumor target.24,47−49 There are a few reports
regarding CA XIII showing that it is involved in the sperm
motility processes50 (probably together with CA XIV) and the
fact that its inhibition may be used in obtaining contraceptive
agents. CA XIV is involved in epileptogenesis and, similarly to
CA IV, in some retinopathies, and may be a drug target for
innovative agents useful in the management of such
disorders.26,51,52
It should be stressed that none of the currently clinically used
CAIs show selectivity for a specific isozyme.2,5 Thus,
developing isozyme-specific CAIs should be highly beneficial
in obtaining novel classes of drugs devoid of various undesired
side-effects. Recently, a large number of structural studies has
provided a scientific basis for the rational drug design of more
selective enzyme inhibitors.53 However, although X-ray crystal
structures are already available for the majority of the twelve
catalytically active members of the human CA family,54−65 most
of the reported complexes with inhibitors regards just isozyme
II, the most thoroughly characterized CA isoform.
The aim of this review is to provide an exhaustive description
of the structural studies on α-CAs so far reported. In particular,
the main structural features of the catalytically active α-CA
isozymes characterized to date will be described and the current
state of the art on complexes of hCA II with the principal
classes of inhibitors will be summarized. A comparison with the
corresponding adducts of other isoforms, when available, will
be also performed, in order to find for each isoform the key
residues responsible for enzyme/inhibitor interaction. Finally,
recent advances in the field of drug design of selective CAIs will
be illustrated.
2. STRUCTURAL FEATURES OF α-CAs
As mentioned above, human catalytically active α-CAs differ for
subcellular localizaton: CA I, II, III, VII and XIII exist in
cytosol, CA IV, IX, XII, and XIV are membrane-associated, CA
VA and VB reside in mitochondria, whereas CA VI is secreted
in saliva and milk (Figure 1).2,5 To date the three-dimensional
structures of all isoforms except CA VB have been
determined.54−65 The analysis of these structures shows that
independently on their subcellular localization and, as expected
on the basis of their high sequence homology (Figure 2), these
enzymes present a similar structure, characterized by a central
twisted β-sheet surrounded by helical connections and
additional β-strands (Figure 3). The active site is located in a
large, conical cavity, approximately wide 12 Å and deep 13 Å,
which spans from the protein surface to the center of the
molecule. The catalytic zinc ion is located at the bottom of this
cavity, exhibiting a tetrahedral coordination with three
conserved His residues and a water molecule/hydroxide ion
as ligands (Figure 3).11,66−68 The Zn2+-bound water molecule/
hydroxide ion is involved in a network of hydrogen bonds
which helps to enhance its nucleophilicity. In particular, it is
hydrogen bonded with the hydroxyl moiety of a conserved Thr
residue (Thr199) and with two water molecules, located on
two opposite sides: the first one, also called the “deep water”, is
located in a hydrophobic cavity delimited by conserved residues
in position 121, 143, 198, and 209, while the second one is in a
hydrophilic environment toward the entrance of the active site
(Figure 4).69 In all the CA isoforms the active site cavity is
divided into two very different environments: the first one is
delimited by a cluster of hydrophobic amino acids, whereas the
other one is lined with hydrophilic residues (Figure 5). Several
studies suggested that these two peculiar active site environ-
ments are responsible of the rapid catalytic cycling of CO2 to
bicarbonate;70 indeed, the hydrophobic region is necessary to
sequester the CO2 substrate and orient the carbon atom for
nucleophilic attack by the zinc-bound hydroxide,70,71 while the
hydrophilic region creates a well ordered hydrogen-bonded
solvent network, which is necessary to allow the proton transfer
reaction from the zinc-bound water molecule to the bulk
solvent (eq 2 and Figure 4).70,72−75 Despite the high sequence
and structural homology among all the isozymes, the
oligomeric state represents a discriminating factor at least for
three of them. Indeed, all the enzymes are monomeric, except
the two membrane-associated isoforms CA IX and CA XII and
the secreted CA VI, which in contrast are dimeric.63,65
Intriguingly, the dimeric structures of these three isoforms are
different, and none influences the catalytic properties of the
enzyme. The observation of a dimeric arrangement in only
three α-CAs is quite surprising and probably suggests that the
oligomeric arrangement of these isoforms responds to the
necessity to perform specific functions in the tissues, where
they are generally present.59,63
3. INSIGHTS INTO CA CATALYTIC MECHANISM: CO2
AND HCO3
− BINDING TO hCA II
Even if in the past a high number of studies provided
hypotheses on the putative binding site of CO2 in the CA active
Figure 1. Schematic illustration of domain composition and
subcellular localization of catalytically active human α-CAs: the
cytosolic CA I, II, III, VII, and XIII and the mitochondrial CA VA
and VB consist only of the CA domain; the membrane-associated CA
IV, IX, XII, and XIV have a transmembrane anchor and, except for CA
IV, also a cytoplasmic tail, while CA IX is the only isozyme with an N-
terminal proteoglycan-like domain; CA VI is secreted and contains a
short C-terminal extension.
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site,71,76−81 the first clear structural evidence on the CO2
binding region was obtained only recently with two
independent crystallographic studies showing the entrapment
of this substrate in the CA II active site.69,70 Figure 6A shows
the binding interactions of CO2 as determined by these
structural studies. In particular, the CO2 molecule is bound in
the hydrophobic side of the active site, in the small pocket
delimited by residues Val121, Val143, Leu198 and Trp209 and
in an orientation that makes it suited for the nucleophilic attack
on the carbon atom by the zinc bound hydroxide ion. One of
the CO2 oxygen atoms lies about in the same position formerly
occupied by the “deep water”, which is now shifted in a new
position, where it establishes novel hydrogen bond interactions
(see Figure 4 and Figure 6A). These structural data are in
agreement with previously reported mutagenesis studies which
demonstrated that substitutions of Val121, Val143, and Leu198
with bulkier residues, leading to the reduction of the volume of
the CO2 binding cavity, caused significant decreases in the
activity.80−83 Interestingly, the presence of the Zn2+ ion seems
to be not important in the binding and orientation of CO2.
70,84
The structure of hCA II/HCO3
− complex was also recently
provided by Sjoblom and co-workers.69 As shown in Figure 6B
the HCO3
− lies in the same plane defined by the CO2 molecule
(Figure 6A) and the Zn2+-bound hydroxide ion and is
tetrahedrally coordinated to the catalytic metal ion through
one of its oxygen atoms. The availability of both hCA II/CO2
and hCA II/HCO3
− complex structures allowed to obtain for
the first time a detailed description of the first step of the
enzymatic reaction providing new perspectives in the structural
studies of this exciting enzyme family.
4. INSIGHTS INTO CA INHIBITION: STRUCTURAL
FEATURES OF ZINC BINDING INHIBITORS
Analysis of all available structural studies for CA/inhibitor
complexes allowed to divide CA inhibitors into two main
classes: those that bind to the enzyme active site anchoring
themselves to the catalytic zinc ion, and those that are bound to
the active site but do not interact directly with the metal ion.
Four different groups of zinc binding inhibitors have been
studied crystallographically: the ureates/hydroxamates, the
mercaptophenols, the metal-complexing anions and the
sulfonamides with their bioisosteres, such as sulfamates and
sulfamides.53 In this chapter the main structural features of the
binding of these molecules to the CA II active site will be
schematically summarized.
Figure 2. Structure-based sequence alignment of α-CAs with known three-dimensional structure. hCA II secondary structure elements are shown
schematically: helices are represented by solid cylinders and β-strands as arrows. Helix and β-strand regions for the various isozymes are highlighted
in red and yellow, respectively. Conserved residues are underlined, catalytic triad, Thr199 and Glu106 are indicated with black triangles, while
residues delimiting the active site cavity are marked with asterisks. β-strand and helix regions are named as reported by Eriksson et al.55 The
following PDB entries were used in the alignment: 1CA2 (hCA II);55 2CAB (hCA I);54 1Z93 (hCA III);61 1ZNC (hCA IV);58 1DMX (mCA VA);57
3FE4 (hCA VI);65 3ML5 (hCA VII);64 3IAI (hCA IX);63 1JCZ (hCA XII);59 3D0N (hCA XIII);62 1RJ5 (mCA XIV).60
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4.1. Binding of Ureates and Hydroxamates
hCA II is not only a very effective catalyst for the
interconversion between carbon dioxide and bicarbonate, but
shows some catalytic versatility, participating in several other
hydrolytic processes which presumably involve nonphysiolog-
ical substrates (see Scheme 1). These reactions include the
hydration of cyanate to carbamic acid (eq 3),85 or of cyanamide
to urea (eq 4),86,87 the aldehyde hydration to gem-diols (eq
5),88,89 the hydrolysis of some carboxylic (eq 6)90−92 or
sulfonic acid esters (eq 7),92 as well as other less investigated
hydrolytic processes (eq 8−11). Among these reactions, the
hydration of cyanamide to urea has been carefully characterized
by means of spectroscopic, kinetic, and crystallographic
techniques.86,87 These studies demonstrated that cyanamide
acts as a weak inhibitor of the esterase activity of hCA II,
interacting with the zinc ion within the enzyme active site.
Interestingly, when hCA II crystals were soaked with cyanamide
for 90 min two different adducts with different occupancy were
observed in the active site. In the high occupancy form the
cyanamide replaces the hydroxide ion coordinating to the zinc
ion with a regular tetrahedral geometry. In the low occupancy
Figure 3. Ribbon diagram of hCA II structure (PDB code 1CA2),
which has been chosen as representative CA isoform. The active site
Zn2+ coordination is also shown. Helix and β-strand regions are
colored in red and yellow, respectively.
Figure 4. The active site of hCA II, which has been chosen as
representative CA isoform. The Zn2+ is tetrahedrally coordinated by
the three catalytic histidines and a water molecule/hydroxide ion,
which is engaged in a well-defined network of hydrogen bonds. Water
molecules are indicated as red circles. The side chain of His64 is
shown in both the in and out conformations.
Figure 5. Solvent accessible surface of hCA II. Residues delimiting the
hydrophobic half of the active site cleft are shown in red (Ile91,
Phe131, Val121, Val135, Leu141, Val143, Leu198, Pro202, Leu204
Val207 and Trp209), while residues delimiting the hydrophilic one are
shown in blue (Asn62, His64, Asn67 and Gln92).
Figure 6. Active site of hCA II showing: (A) the position of CO2
molecule (PDB code 2VVA), (B) the binding of the bicarbonate ion
(PDB code 2VVB). The Zn2+ coordination and polar interactions are
also reported.
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form cyanamide adds to the coordination sphere87 generating a
pentacoordinated adduct together with a zinc-bound water
molecule, which can be considered as a zinc outer-sphere fifth
ligand (Figure 7A). While the first adduct was considered a
dead-end product, the second one represented an intermediate
of the catalyzed reaction, where the hydroxide ion was ready to
perform the nucleophilic attack on the substrate cyanamide
forming urea. In agreement with this hypothesis, when the hCA
II crystals were soaked in cyanamide solutions for several hours,
the reaction took place with the resulting urea which remained
bound to the metal ion (Figure 7B).86 The observation of a
strong binding between urea and the zinc ion has opened the
way to new studies on the interactions of CAs with small
molecules possessing appropriate structural features to act as
zinc binding functions. Among these molecules, N-hydroxyurea
represents one of the simplest compounds.93 The crystallo-
graphic structure of the hCA II/N-hydroxyurea adduct showed
that this molecule binds to the Zn2+ ion of hCA II active site in
a bidentate mode, by means of the oxygen and nitrogen atoms
of the NHOH moiety. Additional hydrogen bonds involving
the hydroxyl and the carbonyl moieties of the inhibitor and the
enzyme residue Thr199 were also observed (Figure 8A).94
Worth noting is that the related acetohydroxamic and
trifluoroacetohydroxamic acids, although containing the same
hydroxamate functionality, were demonstrated to adopt a very
different binding mode. In particular, in the case of
acetohydroxamic acid, the ionized nitrogen was directly
bound to the Zn2+ ion in a tetrahedral coordination (Figure
8B), while in the case of trifluoroacetohydroxamic acid a
fluorine atom and the ionized nitrogen formed a 5-membered
chelate with zinc ion, with a coordination geometry being
approximately trigonal bipyramidal (Figure 8C).95 Altogether
these findings suggest that the hydroxamate moiety represents a
very versatile zinc binding function which can adopt different
binding modes to the metal ion present in the CA active site.
Therefore it could be usefully exploited for obtaining potent
CA inhibitors.
4.2. Thiol Derivatives
Thioxolone (1) is a biologically active compound, classified as
an antiseborrheic agent96 largely used in the treatment of acne
and dandruff.97 Cytostatic,98 antipsoriatic, antibacterial, and
antimycotic activities96 were also reported as medically useful
properties of this molecule. A screening study on a series of
biologically active compounds against hCA II led to identify
this molecule as a weak inhibitor for this enzyme.99 Since 1
does not contain any functional group typically found in
therapeutic CA inhibitors, several biochemical and structural
studies were devoted to understand its inhibition mechanism. A
preliminary characterization revealed that 1 acts as a weak hCA
II inhibitor, both in a kinetic esterase assay with the substrate 4-
nitrophenyl acetate (4-NPA) and in a competitive binding assay
with dansylamide (IC50 value of 1.8 μM and Kd value of 33
Scheme 1. Examples of Known Reactions Catalyzed by hCA
II
Figure 7. Representation of the binding mode of (A) cyanamide (PDB
code 1F2W) (pentacoordinated adduct), and (B) urea (PDB code
1BV3) to the hCA II active site.
Figure 8. Schematic representation of (A) N-hydroxyurea (PDB code
2GEH), (B) acetohydroxamic acid (PDB code 1AM6), and (C)
trifluoroacetohydroxamic acid to the hCA II active site.
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μM).100 The inhibition mechanism of this molecule was not
immediately clear analyzing its chemical structure but crystallo-
graphic studies helped to clarify it.100 In particular, in hCA II
crystals soaked with 1, the latter was not found in the active
site, which instead contained a 4-mercaptobenzene-1,3-diol
molecule (2) bound to the catalytic zinc ion (Figure 9). This
observation led to hypothesize that when thioxolone binds to
the hCA II active site, it is cleaved forming 4-mercaptobenzene-
1,3-diol via the intermediate S-(2,4-thiophenyl)hydrogen
thiocarbonate (see Scheme 2) utilizing, as hypothesized for
other esters,101 a hCA II zinc-hydroxide mechanism.100 The
main stabilizing interactions observed in the so-formed hCA II/
2 adduct are schematically depicted in Figure 9. The inhibitor is
coordinated to the zinc ion through its thiol group, which also
forms a weak hydrogen-bond with Thr199OG1 atom, similarly
to the interaction previously observed in several sulfonamide/
sulfamide/sulfamate complexes.53 The phenyl ring is stabilized
by several van der Waals interactions with active site residues,
while the hydroxyl group in para-position to the thiol moiety
points toward a hydrophobic pocket delimited by residues
Ile91, Phe131, Val135, Leu141, and Leu198 and establishes a
series of nonfavorable interactions. These findings prompted
the authors to investigate also some thioxolone structural
analogues as hCA II inhibitors, such as the thioxolone
hydrolysis product 2, and the two smaller related compounds
2-hydroxythiophenol (3) and benzenethiol (4). The latter two
compounds behaved as hCA II inhibitors in a 4-NPA esterase
assay with IC50 values of 1.05 and 1.49 μM, thus appearing
more potent inhibitors than the parent compound, thioxolone.
Inhibition constants of 1, 2, and 3 were also determined for the
physiologically relevant reaction of CO2 hydration. In this case
KI values of 314, 148, and 0.631 μM for 1, 2, and 3, respectively
were determined. These results further confirmed that
thioxolone is a relatively weak inhibitor of hCA II activity,
whereas its hydrolysis product 2, although still a relatively weak
inhibitor, is twice more potent. Again, 3 shows a significant
500-fold increase in inhibition, similar in magnitude to other
sulfonamide inhibitors. This result suggested that the absence
of the hydroxyl group in para-position to the thiol moiety of 2
may have greatly improved the affinity of this molecule toward
the CA active site, in agreement with structural studies
described above, which highlighted the incompatibility of the
hydrophilic nature of this group in the hydrophobic pocket.
In conclusion, these studies demonstrate that mercaptophe-
nols represent a class of compounds with good CA inhibitory
properties,100,102 even if they lack functional groups typically
found in therapeutically used CA inhibitors.
Figure 9. Schematic representation of the active site region in the hCA
II/2 complex (PDB code 2OSF). Residues involved in inhibitor
recognition are shown. The hydrophobic pocket which accommodates
the hydroxyl group in para-position to the thiol moiety is highlighted
in bold.
Scheme 2. Thioxolone Hydrolysis Catalyzed by hCA II
Figure 10. Representation of the three different Zn2+ coordination geometries of some representative anions: (A) hydrogen sulfide (PDB code
1CAO), (B) bromide (PDB code 1RAZ), and (C) thiocyanate (PDB code 2CA2). Hydrogen bonds are represented as dotted lines, whereas zinc ion
coordination as solid lines.
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4.3. Metal-Complexing Anions
Inorganic anions constitute a well-known class of CAIs. They
are usually weak inhibitors with affinities in the millimolar-
submillimolar range, with a few anions arriving to be low
micromolar inhibitors for some isoforms (e.g., cyanide, azide,
hydrogen sulfide and trithiocarbonate).2,11,53,103
Crystallographic studies have shown that inorganic anions
can bind within the CA II active site, either coordinating the
catalytic Zn2+ ion or not coordinating it, but being located in its
close proximity in a nonmetal site.2,11,53,104,105 When these
anions coordinate the Zn2+ ion, three different coordination
geometries have been observed: regular tetrahedral,66,105
distorted tetrahedral103,106,107 and trigonal bipyramid.55,66
This different behavior can be ascribed to the structural
features of the ligands. In particular, anions able to act as
hydrogen-bonding donor toward the active site residue Thr199,
such as hydrogen sulfide (HS−)105 and hydrogen bisulfite
(HSO3
−),66 replace the zinc-bound water/hydroxide adopting a
regular tetrahedral coordination geometry (Figure
10A).53,66,105,108 Unprotonated ligands can adopt either
distorted tetrahedral or trigonal bipyramid coordination
geometry. In particular, anions as bromide (Br−),106 and
azide (N3
−)106,107 still coordinate to the zinc ion replacing the
zinc bound water/hydroxide. However, since these inhibitors
cannot form a hydrogen bond with Thr199OG1, the
coordination around Zn2+ is significantly distorted from a
regular tetrahedral geometry (Figure 10B).106,107 Finally, anions
as formate66 and thiocyanate109 bind to the enzyme active site
by addition to the metal coordination sphere, shifting the zinc-
bound solvent molecule and generating a distorted trigonal
bipyramid geometry (Figure 10C).66,109
4.4. Sulfonamides
To date, the sulfonamide group (R-SO2NH2) is the most
important and largely used zinc binding function for the design
of CAIs; accordingly, the majority of the clinically used CAIs
are sulfonamides. Since the first evidence of their CA inhibitory
properties,110 these molecules were largely investigated by
means of kinetic, physiological and pharmacological stud-
ies.2,5,10,25,53,111 Crystallographic studies are also available for
many of their adducts with several CA isozymes,53,63,64
elucidating the key factors responsible for the binding of the
sulfonamide moiety to the CA active site and providing a
rationale for the unique tailored properties of this anchoring
group. In all the studied adducts the binding of the sulfonamide
derivatives is mainly driven by the coordination of the
deprotonated sulfonamide nitrogen to the catalytic Zn2+
ion,112 with consequent substitution of the zinc-bound water
molecule, and by two H-bonds of the sulfonamide moiety with
residue Thr199 (Figure 11).13,67,108,113 Furthermore, depend-
ing on the nature of the R substituent, additional interactions
with the hydrophilic and/or hydrophobic region of the active
site can be also present (Figure 11).53 These studies highlighted
that the sulfonamide group is an ideal ligand of the CA active
site for two main reasons: on one hand, it combines the
negative charge of the deprotonated nitrogen with the
positively charged zinc ion, on the other hand, the presence
of one proton on the coordinated nitrogen atom satisfies the
hydrogen bond acceptor character of Thr199OG1 atom, which
forms a strong H-bond with it.5,53
4.4.1. Benzenesulfonamides. The first evidence that
sulfonamides could act as potent CAIs came from a study,
reported by Mann and Keilin in 1940,110 on sulfanilamide 5.
Subsequently, many aromatic sulfonamides were synthesized
and investigated for their CA inhibitory action.114 Among these,
benzenesulfonamides, of which 6 is the prototype, constitute
the most common and best characterized class. To date, a very
large number of studies has been reported on the interaction of
these molecules with CA II active site, which allowed to obtain
the following structure−activity relationships: (i) 2-substituted,
2,4-, and 3,4-disubstituted benzenesulfonamides behave gen-
erally as weaker inhibitors compared with 4-substituted
derivatives; (ii) 4-substituents inducing good activities include
halogens, acetamido and alkoxycarbonyl moieties as well as
esters of 4-sulfamoylbenzoic acid; (iii) good inhibitory
properties and interesting physicochemical features were
observed for compounds possessing carboxy-, hydrazido-,
ureido-, thioureido-, and methylamino-moieties in position
4.53,114−116 Several structural studies on the adducts that
benzensulfonamides form with hCA II have also been published
and have provided an unambiguous view of the molecular
determinants responsible for the enzyme−inhibitor interac-
tions.5,11,25,53,104 Interestingly, in nearly all the studied adducts,
the interaction of the benzenesulfonamide moiety with the
enzyme active site is rather similar, with the sulfonamide moiety
involved in the canonical coordination of the Zn2+ catalytic ion
(see above) and the phenyl ring, which establishes several van
der Waals interactions with residues Gln92, Val121, Phe131,
Leu198, and Thr200 (Figure 12). On the contrary, depending
on their nature and position, the substituents of the phenyl ring
Figure 11. Schematic illustration of the key interactions between a
generic sulfonamide inhibitor and the hCA II active site.
Figure 12. Schematic representation of the binding mode of the
benzenesulfonamide 6 with the hCA II active site (PDB code 2WEJ).
Residues establishing van der Waals interactions (distance <4.5 Å)
with the inhibitor phenyl ring are also shown.
Chemical Reviews Review
dx.doi.org/10.1021/cr200176r | Chem. Rev. 2012, 112, 4421−44684428
can establish different types of interactions which involve the
hydrophobic and/or the hydrophilic region of the active site. In
the following paragraphs the numerous CAIs belonging to the
benzenesulfonamide class will be reviewed, highlighting the
main structural determinants responsible of their hCA II
inhibitory properties. To simplify the discussion, these
molecules will be grouped on the basis of either the functional
groups used to derivatize the phenyl ring, or their biological
action.
4.4.1.1. Halogenated Benzenesulfonamides. Introduction
of halogen atoms as substituents in various positions of the
benzene ring of benzenesulfonamides has been largely
investigated from diverse points of view. Several studies
suggested that the presence of such electronegative substituents
exerts an acidifying effect on the sulfonamide protons, which is
thought to be correlated with an increase in the CA inhibitory
properties.5,53,117 Consequently, although this seems not to be
always true,117 the presence of one or more halogen atoms in
the scaffold of a benzenesulfonamide CAI is usually correlated
with efficient inhibition of many isoforms, such as CA I, II, VII,
IX, XII, etc.117,118 A detailed study on the way in which chlorine
and/or fluorine atoms present in the benzenesulfonamide
scaffold influence the binding mode to the enzyme and
consequently the thermodynamics of binding has been recently
reported by Scott and co-workers.119 In this study, the
crystallographic structures of benzenesulfonamide 6 and its
chloro-/fluoro-substituted derivatives 7−9 in complex with
hCA II were reported and correlated with an isothermal
titration calorimetry (ITC) analysis, highlighting that often very
similar substituents (e.g., F or Cl in position 2 or 3) can cause
important differences on the binding mode to the enzyme (see
Figure 13) and consequently significant changes in the
thermodynamics of binding.119
These findings showed the difficulties in the prediction of the
effect of a substitution on the phenyl ring of the
benzenesulfonamide scaffold and highlighted the helpfulness
of a combined thermodynamic and structural approach in the
rational drug design of new CAIs.
4.4.1.2. Sulfamoyl-Benzenecarboxamides. Sulfamoyl-ben-
zenecarboxyamides of type 10 and 11 represent an important
class of CAIs obtained by reaction of 4-carboxy-benzenesulfo-
namide (12) or 4-chloro-3-sulfamoyl benzoic acid (13) with
different molecules containing primary amino groups.120−132
The nature of the R group can be very different: it can vary
from a peptide tail to an aliphatic spacer, and depending on its
features the corresponding inhibitors present different affinity
toward various CA isozymes as well as diverse physicochemical
properties.
Initial studies on this class of derivatives were performed by
Whitesides and Christianson groups, which investigated the
derivatization of 12 with oligopeptide tails, generating
compounds of type 14, 15, and 16.121,123,127−129,131 The aim
of such studies was the development of tight-binding inhibitors,
which, beyond establishing the canonical interactions of the
benzensulfonamide moiety with the Zn2+ ion and its
neighboring residues, would be able to interact with hydro-
phobic “patches” present at the border of the CA II active site
cavity.121,123,127−129,131 Such hydrophobic patches were defined
by the molecular surfaces of Phe131 on one hand and of the
three adjacent residues, Leu198, Pro201, and Pro202 on the
opposite face. Structural studies121,127 showed that, when these
compounds interacted with the enzyme active site, the
oligopeptide tails did not engage in any intermolecular
hydrogen bond but established only van der Waals interactions
with the aforementioned hydrophobic patches. At the same
time kinetic studies121 suggested that such hydrophobic
interactions contributed to improve the binding constants by
a factor 102−103 with respect to the simple 4-sulfamoylbenza-
mide, even though the strength of interaction was rather
insensitive to the chemical structure of the tail. Finally, attempts
to design molecules capable of binding simultaneously both
hydrophobic patches did not lead to inhibitors with higher CA
affinity than those able to bind these sites individually,
Figure 13. Superposition of hCA II/inhibitor adducts: 6 is reported in
blue (PDB code 2WEJ), 7 in yellow (PDB code 2WEH), 8 in green
(PDB code 2WEG) and 9 in red (PDB code 2WEO). This picture
shows as the aromatic ring orientation is conserved for 6, 8, and 9,
whereas the phenyl moiety is twisted in the case of 7, allowing the
chlorine substituent to better interact with the hydrophobic side of the
hCA II active site. The enzyme is represented as a surface-model
(hydrophobic side in red, hydrophilic side in blue).
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highlighting once again the difficulties to predict effects of
chemical structure on inhibitory properties.
Subsequently, Supuran and co-workers reported another
series of compounds where the derivatization of 12 and 13 was
obtained by reaction with amino acid/dipeptide tails.120 These
compounds showed nanomolar affinity for CA II and CA IV,
the two CA isoforms involved in aqueous humor secretion
within the eye. Since some of these compounds had a very
good penetrability through the cornea, as a result of their good
hydrophilicity/lipophilicity balance, they were easily formulated
as eye drops either in solution or as suspensions, showing very
good in vivo efficacy in animal models of glaucoma as
intraocular pression lowering agents.120
Another kind of benzenecarboxamide derivatization was
obtained with the attachment of oligoethylene glycol units to
12, generating CAIs of type 17.128 The effect of the length of
repeating ethylene glycol (EG) units was kinetically inves-
tigated. These studies showed that dissociation constants
increased only very slightly on increasing the number of the
EG units, despite the fact that the inner (EG)n moieties (n =
1−3) interacted sufficiently with the protein to influence
proton relaxation times, thus suggesting that eventual improve-
ment in ΔH could be canceled by corresponding worsening in
ΔS.128,129 Further derivatization of 17 with amino acid residues
led to compounds of type 18.129 Some of these last compounds
were studied in their association with CA II by X-ray
crystallographic methods showing that the observed differences
in the values of the dissociation constants were not due to
differences in metal ion coordination or to a diverse binding
mode of the EG moieties to the enzyme, but instead arised
from the capability of the pendant amino acid to interact with
the protein surface. Overall these studies suggest that structural
variations of inhibitors even at sites very distant from the
sulfonamide moiety can significantly affect binding affinities.129
In this context it can be included also a recent study of
Srivastava and co-workers, where the derivatization of 12 with a
functional group supposed to interact with the surface exposed
His residues of the CA enzymes,124,125,130 has allowed to obtain
very strong CA inhibitors of type 19 and 20.124,125 In these
molecules the benzenesulfonamide is conjugated to the
iminodiacetate-Cu2+ (IDA-Cu2+) moiety via a spacer group,
enhancing significantly the enzyme−inhibitor affinity. This
“two-prong” approach was expected to provide a general
strategy for converting weak inhibitors of enzymes into tight-
binding ones. X-ray crystallographic studies of the hCA II/20
adduct (Figure 14) revealed that, as expected, the benzene-
sulfonamide moiety was coordinated to the Zn2+ similarly to
other benzenesulfonamide inhibitors, while the IDA-Cu2+
prong was bound to His64, thus demonstrating that the high
inhibition power of the inhibitor against CA II was related, in
Figure 14. Ribbon diagram of the hCA II/20 complex (PDB code
2FOV). The inhibitor benzenesulfonamide moiety is coordinated to
the catalytic zinc ion, while its IDA-Cu2+ prong is bound to His64
residue that adopts the “in” conformation.
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addition to the displacement of the catalytic nucleophile, to the
inhibition of the catalytic proton shuttle His64.125
4.4.1.3. Benzenesulfonamides Containing Ureido and
Thioureido Moieties. Benzenesulfonamides containing an
ureido or thioureido moiety of type 21 and 22 represent an
interesting class of recently reported CAIs, which possess
peculiar CA inhibitory properties.133−137 Indeed, initial kinetic
experiments showed that many of these molecules, differently
from most of the previously reported sulfonamide CAIs,
presented selective inhibition of hCA I over hCA II, thus
representing good lead molecules for developing more selective
CA I inhibitors.138 Nevertheless, up to now this class of
molecules has been only poorly characterized from a structural
point of view and a few structure−function relationship studies
are available. In the ureido-derivative class, compounds 23−27,
which have been obtained by reaction of 4-aminobenzene-
sulfonamide 5 with different aryl/alkyl isocyanates,137 are
among the most thoroughly investigated examples. Inhibition
assays against hCA II showed for these structurally related
molecules a great variability in the KI values, which spanned the
range 3−226 nM.137 The structural reasons of such variability
were investigated by solving the X-ray structures of all these
derivatives in complex with hCA II.137 The comparative
analysis of these structures showed that all the benzenesulfo-
namide groups of the five inhibitors established the canonical
interactions with the enzyme active site and were rather well
superimposable. On the contrary, the various tails presented
different orientations, even if all pointed toward the exterior of
the active site. In particular, in the molecules 23, 24, and 27 the
4-fluorophenyl, pentafluorophenyl and cyclopentyl groups were
oriented toward the hydrophobic region delimited by residues
Val135, Leu198, and Leu204 (Figure 15A,B,E). In molecule 26
the 3-nitrophenyl moiety was still located in a hydrophobic
pocket, delimited by residues Ile91 and Val121, but which was
separated from that occupied by the tails of 23, 24, and 27 by
residue Phe131 (Figure 15D,F). Finally, the 2-isopropylphenyl
tail of compound 25 was involved into an edge-to-face
interaction with Phe131, assuming a position intermediate
between those observed for 23, 24, and 27 on one side and 26
on the other (Figure 15C,F).137 The great variability observed
Figure 15. Active site representation of hCA II in complex with (A) 23 (PDB code 3N4B), (B) 24 (PDB code 3N0N), (C) 25 (PDB code 3N3J),
(D) 26 (PDB code 3N2P), and (E) 27 (PDB code 3MZC). (F) shows the superposition of the five ureido-derivatives (23 in yellow, 24 in green, 25
in cyan, 26 in orange, and 27 in blue). hCA II is represented as a surface-model (hydrophobic region, red; hydrophilic region, blue). Phe131 is also
reported as ball-and-stick in red.
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in the orientations of all these tails within the hCA II active site
could be ascribed to the high flexibility of the ureido fragment.
Indeed, the torsion angles between the benzensulfonamide
group and the second ring (see Figure 15A,B,C,D,E) were very
different among all the five investigated compounds. Thus, the
high flexibility of the ureido linker could allow the inhibitor to
adopt different conformations, selecting the most energetically
favored hydrophobic region to bind.137
The structurally related thioureas of type 22 can be obtained
from isothiocyanatosulfonamides and amines, hydrazines or
amino acids.133−136 Some of these compounds have shown
interesting features such as a good water solubility and a potent
inhibitory activity against the ubiquitous isozyme hCA II and
the transmembrane, tumor-associated hCA IX, representing
thus interesting candidates for the design of antiglaucoma/
antitumor agents.133−136 However, as for the ureido-derivatives,
only a few structural data on the binding mode of these
molecules to the CA active site have been reported so
far.139−141 N-1-(4-Sulfamoylphenyl)-N-4-pentafluorophenyl-
thiosemicarbazide 28 is an interesting member of this class,
which has been demonstrated to act as an efficient inhibitor for
hCA I (KI value of 78 nM), and very good for hCA II and hCA
IX (KI values of 19 and 15 nM, respectively).
139 The X-ray
crystal structure of hCA II/28 complex showed the canonical
binding mode of the benzenesulfonamide group to the active
site with the thioureido moiety making strong van der Waals
contacts with residues Phe131, Val135, Leu198, Pro202, and
Leu204 (Figure 16A), and the pentafluorophenylamino tail,
pointing toward the same hydrophobic pocket occupied by the
tail of compounds 23, 24, and 27 (Figure 16B).139
Unfortunately, the absence of structural studies on other
thioureido compounds, possessing different tails and linkers,
does not allow a detailed analysis of the potential binding sites
of the tails as well as of the flexibility of the linker. Further
studies are necessary to clarify this point.
4.4.1.4. Charged Benzenesulfonamides. As already men-
tioned in the Introduction, although many benzenesulfonamide
CAIs possess high affinity for the different CA isoforms, the
critical challenge for the design of new pharmacological agents
is constituted by the lack of specificity of such compounds. An
interesting approach to overcome at least in part this problem
was proposed by Supuran and co-workers.142−148 Indeed, these
authors suggested that sulfonamides with a permanent positive
charge, due to their cationic nature, would be unable to
penetrate through biological membranes and therefore would
inhibit in vivo only CA enzymes located on the outer surface of
the membranes, such as the extracellular isoforms CA IV, IX,
XII, and XIV. Thus, a large series of such compounds was
prepared by reaction of aromatic sulfonamides possessing a
primary amino, imino, hydrazino, or hydroxyl group with
Figure 16. (A) Active site region in the hCA II/28 adduct139 showing
residues participating in recognition of the inhibitor molecule.
Hydrogen bonds and the catalytic Zn2+ coordination are also shown.
(B) View of the tail orientation of 28 within hCA II active site. The
enzyme is represented as a surface-model (hydrophobic region, red;
hydrophilic region, blue). Phe131 is also shown as ball-and-stick in red.
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pyrylium salts, affording compounds of type 29 and
30.145−147,149 These compounds were demonstrated to
efficiently inhibit in vitro several CA isoforms, thus not
showing any significant isozyme selectivity.142,143,146,148 How-
ever, in vitro and ex vivo experiments demonstrated that such
derivatives were unable to cross the plasma membrane,
confirming the design hypothesis.143,146,147 Such data are
extremely important for specific in vivo inhibition of
membrane-associated CA isozymes, especially the tumor
associated CA IX and CA XII, and consequently for the
eventual development of novel anticancer drugs.
1-N-(4-Sulfamoylphenyl-ethyl)-2,4,6-trimethylpyridinium
perchlorate 31142,146,150 is one of the most interesting
derivatives of this series. Indeed, although kinetic studies
demonstrated that this molecule is able to inhibit several CA
isoforms in the nanomolar range (KI values of 4, 21, and 14 nM
against CA I, II, and IX, respectively),142 because of its
membrane impermeability, in vivo it could interact only with
membrane-associated isozymes without appreciable inhibition
of the cytosolic isoforms.150 More interestingly, 31 was also
shown to diminish in vitro the acidification of hypoxic tumors
overexpressing CA IX, thus constituting an interesting lead
compound for the design of antitumor sulfonamides.151
The X-ray crystal structure of the hCA II/31 complex was
solved, providing interesting insights into the molecular basis
responsible for its CA affinity.150 In particular, the analysis of
this structure showed that while the benzenesulfonamide
moiety was involved in the canonical interactions within the
active site cavity, the 2,4,6-trimethylpyridinium moiety
established several other important interactions. Indeed, this
group was located in the same hydrophobic pocket occupied by
the tail of ureido-derivative 26, making van der Waals
interactions with Ile91 and establishing a strong face-to-face
stacking interaction with Phe131 side chain (Figures 15D and
17). These findings, together with those reported in the
previous paragraph, evidenced a key role for residue Phe131 in
the orientation of the inhibitor molecule in the CA II active site.
Since the different CA isozymes present diverse amino acids in
position 131, this residue could represent a target to achieve
inhibitors with higher isozyme selectivity.
The effect of the presence of a positive, negative or neutral
substituent on benzenesulfonamide CAIs has been investigated
in detail also by Srivastava’s group. In this case, the aim was to
understand the effect of different charges in the CA I and CA II
active sites, to discriminate the binding to these two
isoforms.152 In particular, four simple benzenesulfonamide
inhibitors, specifically compounds 32−35, substituted at the
para position with differently charged functional groups, were
synthesized. The substituents were chemically different and
were designed to bind in the midsection of the active site, in
order to explore their features also as possible molecular linkers
connecting the benzenesulfonamide moiety and a second
functional group in a “two prong” approach (see section
4.4.1.2). The affinities and X-ray crystal structures of the
complexes that these compounds formed with hCA I and hCA
II were determined, revealing that a positively charged amino
group was more poorly tolerated in the active site of CA I
compared with CA II, while a negatively charged carboxylate
substituent was tolerated equally well in the two active sites.
However, in both cases enzyme−inhibitor affinity improved
Figure 17. Representation of active site region in the hCA II/31
complex (PDB code 1ZE8) showing hydrophobic residues involved in
the recognition of the inhibitor molecule (distance <4.5 Å). Hydrogen
bonds and the active site Zn2+ coordination are also shown.
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upon neutralization of inhibitor charged groups by acylation or
esterification.152 These studies provided important indications
into the choice of molecular linkers that could potentially be
used to alter the binding properties of bifunctional inhibitors.152
4.4.1.5. Benzenedisulfonamides. The presence of a second
sulfonamide group in benzenesulfonamide derivatives has been
largely investigated both in the search of more active CAIs and
to develop compounds with a different biological activity (the
CA inhibitory action being less important in the second case).53
Two different types of such derivatives have been so far
characterized: those where the two sulfonamide moieties are
present on the same phenyl ring (see compounds 36−38)153
and those where the two sulfonamide moieties are present on
two different phenyl rings, separated by urea, guanidine,
carboxyamido moieties etc., as spacers (see compounds
39).53,154,155
Dichlorophenamide 36, which has been largely clinically used
for the treatment of glaucoma15,114,156 and several neurological
disorders,114,157 and its closely related analogues 6-chloro-4-
amino-benzene-1,3-disulfonamide 37 and 6-trifluoromethyl-4-
amino-benzene-1,3-disulfonamide 38 are examples of the first
type of such derivatives. These compounds, that were all
demonstrated to act as nanomolar inhibitors of hCA II, were
extensively characterized from a structural point of view.153 In
particular, the high resolution structures of these three
compounds in complex with hCA II153 revealed for all of
them a particular binding mode within the enzyme active site.
Figure 18 shows the key interactions which stabilize the binding
of these compounds to the enzyme. In particular, beyond the
canonical coordination of the Zn2+ ion by means of the ionized
sulfonamide NH− group, the substituted phenyl moiety of each
inhibitor makes various van der Waals and hydrogen bond
interactions with residues delimiting the cavity. In all three
complexes the meta-sulfonamide group is oriented toward the
hydrophilic side of the active site cleft and establishes several
hydrogen bond interactions. Such interactions force the plane
of the phenyl moiety to assume an orientation rotated by ∼45°
and tilted by ∼10° with respect to that generally observed in
other CA II/benzenemonosulfonamide complexes53 and
described in section 4.4.1 (Figure 19). These findings suggest
that the presence of an additional sulfonamide group in meta-
position of benzenesulfonamide CAIs can be utilized to
differently position the phenyl moiety within the active site
and to opportunely orient a putative tail of the phenyl ring,
allowing the exploration of active site regions different from
those usually occupied by tails of the classical benezenemono-
sulfonamide inhibitors.153
4-(4-Sulfamoylphenylcarboxamidoethyl)benzenesulfonamide
40 is a representative compound of the class of bis-
sulfonamides of type 39. Such a molecule has been
demonstrated to act as a topically acting antiglaucoma drug,
with strong inhibition properties toward hCA II (KI of 5
nM).120 The X-ray crystal structure of the hCA II/40 adduct
has been solved, providing insights into the interaction mode of
this type of inhibitors with the enzyme.155 Indeed, the structural
analysis highlighted that the two sulfamoyl moieties of the
inhibitor allow for its optimal orientation within the active site,
with the first one which binds in ionized form to the zinc ion,
the organic part lying in the hydrophobic region of the active
site and with the terminal, carboxyamido containing phenyl-
sulfamoyl head participating in strong hydrogen bonds with
residues located at the entrance of the active site cavity (Figure
20).155 On the basis of these findings it is conceivable that
modifications of organic scaffold of 40 (such as the substitution
pattern of the two phenyl rings, the nature and the length of the
linker between them etc.), designed to optimize the interaction
with the different residues present in the active site of the
diverse CA isoforms, could in principle lead to more selective
CAIs with different type of applications.155
4.4.1.6. Benzenesulfonamides Derivatized with Fluores-
cent Probes. In the past a lot of research on CAs was
concentrated on the study of the involvement of these enzymes
in different type of tumors. Such studies identified first hCA
IX158 and later hCA XII159,160 as the CAs associated to tumors.
Among these two isoforms, CA IX was considered of particular
interest for its peculiar features; indeed this enzyme is present
only in a limited number of normal tissues (mainly in the
gastrointestinal tract) (see Table 1), whereas it is overexpressed
in hypoxia and during development of various human
carcinomas,161 thus representing a valuable target for cancer
diagnosis and treatment. In this context, the ability to detect the
overexpression of this protein, that identifies a population of
abnormal cells, has the potential to improve the accuracy and
efficacy of early cancer detection. Toward this goal, the selective
recognition of this protein by different kinds of molecular
probes, such as fluorescent, spin-labeled and129Xe-based
probes, has been largely exploited in the last period.140,162,163
However, since the crystal structure resolution of CA IX has
only recently been achieved,63 the rational design of such
probes has been mainly performed by using the structural
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information derived from the most common and easily
crystallizable isoform, that is, CA II. The rationale for
developing such molecular probes was to attach moieties
which confer specific physicochemical properties (e.g.,
fluorescence, free radical character, etc.) to sulfonamide CA
inhibitors, which should preferentially bind to CA IX and
XII.151,163
The development of several fluorescent CAIs has been
reported. Fluorescein is an optimal moiety for designing such
compounds, since it presents an appropriate excitation and
emission wavelength, when present in various biologically active
derivatives (i.e., 495 and 519 nm, respectively) and the
synthesis of such compounds is rather straightforward.
Preliminary studies on this topic were reported in 1996 by
Christianson’s group.164 In particular, starting from the crystal
structure of the CA II/arylsulfonamide 41 complex,164 these
authors adopted an iterative structure-based procedure for the
rational design of the fluorescein-derivatized arylsulfonamide
probe 42. However, in the three-dimensional structure of the
CA II/42 complex, although 42 was able to tightly bind to the
enzyme (Kd = 2.3 nM), the fluorescein moiety was not able to
establish direct interactions with it. The strength of binding was
therefore attributable only to the canonical interactions of the
benezenesulfonamide moiety and to some hydrophobic
interactions of the linker, connecting the fluorescein and the
benzenesulfonamide moieties, with residues Leu198, Pro202,
and Phe131.164 The analysis of the structure suggests that the
Figure 18. Schematic representation of the binding mode of sulfonamides 36 (A), 37 (B), and 38 (C) within the hCA II active site (PDB codes
2POU, 2POV, and 2POW for 36, 37, and 38, respectively).
Figure 19. Superposition of benzenedisulfonamides 36−38 (36
yellow, 37 red, and 38 orange) with the benzenesulfonamide 6
(blue; PDB 2WEJ). hCA II is represented as a surface-model and the
catalytic zinc ion as a gray sphere.
Figure 20. View of the active site region in the hCA II/40 complex
showing residues participating in recognition of the inhibitor molecule.
Hydrogen bonds and the active site Zn2+ coordination are also shown.
The PDB coordinate file has been kindly provided by Claudiu T.
Supuran.
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absence of a direct interaction of the fluorescein moiety with
the active site could be related to the excessive length of the
linker which brings the fluorescein moiety out of the active site
cavity.
More recently Supuran’s group reported the development of
a new series of fluorescent sulfonamides of type 43a−43j,163
characterized by the presence of a fluorescein moiety, a
benzenesulfonamide variously substituted, and a thioureido
moiety as linker. One of the most interesting compounds in this
series was the derivative (4-sulfamoylphenylethylthioureido)-
fluorescein (43h).140 Indeed, this derivative, besides showing
strong capability to bind the cytosolic hCA II isozyme (Kd =
0.64 nM),140 presented even higher affinity for the tumor-
associated CA IX (Kd = 0.30 nM).
140 For this reason, it is
actually in clinical studies as an imaging tool for acute hypoxic
tumors.151 The X-ray crystal structure of 43h in complex with
the cytosolic isoform hCA II has been reported together with a
modeling study of the adduct which this inhibitor forms with
the isoform hCA IX.140 The crystallographic analysis showed
that, beyond the canonical interactions of the benzenesulfona-
mide group within the hCA II active site, the thioureido moiety
established strong van der Waals interactions with residues
Gln92, Val121, Phe131, Val135, Leu198, Thr199, Thr200, and
Pro202 (Figure 21A). Moreover, differently from what
observed for compound 42, in this case the bulky fluorescein
moiety was well-defined in the electron density maps, being
located at the rim of the active site, on the protein surface,
strongly interacting with the α-helix formed by residues
Asp130-Val135 (Figure 21B). Molecular modeling studies of
the corresponding adduct with hCA IX revealed that all these
interactions were preserved in the binding to hCA IX, even if an
additional polar interaction was observed. In particular, in the
latter case the carbonyl moiety of the fluorescein tail
participated in a strong hydrogen bond with the guanidine
moiety of Arg130, an amino acid characteristic of the hCA IX
active site (Figure 22). This interaction is probably responsible
for the roughly twice higher affinity of 43h for hCA IX over
hCA II and could explain why in vivo the compound specifically
accumulated only in hypoxic tumors overexpressing CA IX and
not in the normal tissues.140
4.4.1.7. Benzenesulfonamides Derivatized with Spin-
Labeled Probes. Electron paramagnetic resonance (EPR)
techniques have been largely used for the investigation of
protein conformations and their changes in different
milieus.165,166 Moreover, such techniques can be also utilized
to study inhibitor binding to an enzyme active site, since such
molecules have different mobility depending on whether they
are free in solution or they are bound to the target enzyme, and
can therefore show major changes in their EPR spectrum when
complexed to the enzyme. For these reasons, in recent years a
great attention has been dedicated to the development of CAIs
containing a free-radical moiety active in EPR measurements.
The development of such inhibitors, if associated to a certain
degree of selectivity for isoform CA IX, can represent an
Figure 21. (A) Representation of 43h binding within the hCA II active site (PDB code 2F14). (B) Ribbon diagram of the hCA II/43h adduct
showing as the fluorescein moiety, located at the rim of the active site, strongly interacts with the α-helix formed by residues Asp130-Val135 (α-helix
is colored in red).
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interesting tool for the investigation of hypoxic tumors by EPR
techniques.
Preliminary studies on spin-labeled CAIs were reported in
70s with the aim to derive structural information on the CA
active site,167−171 since in those years no structural information
was available on any CA isoform alone or in complex with
inhibitors. On the contrary, more recently, with the aim to
investigate new strategies for the labeling of tumor associated
CAs, a new series of derivatives (44a−44i) has been generated
by using the classical tail strategy. In such derivatives the spin-
labeled 2,2,6,6-tetramethylpiperidine-1-oxyl (TEMPO) moiety
is inserted as tail in a classical benezenesulfonamide scaffold, by
using thiourea as linker.172
The TEMPO group was chosen as free radical moiety in
these molecules for its advantageous features in EPR experi-
ments. Indeed it possesses a simple EPR spectrum,173 shows a
high stability, and induces a relatively good water solubility to
the compounds incorporating it. Moreover, its spectral
properties (such as line width and intensity) can be modulated
in in vivo experiments by tissue oxygen or redox status.173,174
Compounds 44a−44i were tested for their inhibitory
properties against hCA I, hCA II and hCA IX, showing
generally an efficient inhibition of hCA II and hCA IX (KI in
the range of 12−76 nM) and only a moderate inhibition of
hCA I (KI in the range of 132−2070 nM).175 The crystal
structure analysis of 44c, one of the best CA II inhibitors of the
series, in complex with hCA II was also solved providing
detailed information on the inhibition mechanism of this class
of molecules.141 In particular, the structural analysis revealed
that beyond the classical interactions of the benzenesulfona-
mide moiety, only a few additional hydrophobic interactions
between the thioureido linker and the hydrophobic region of
the active site were present (Figure 23). Indeed, the TEMPO
moiety showed a certain degree of flexibility and thus was not
entirely visible in the electron density maps.141
EPR spectra of three representative compounds of this series,
namely 44b, 44c, and 44e, were recorded in the presence and
in the absence of CA II.141 In absence of the enzyme the three
spectra were all superimposable, in agreement with the fact that
their structural differences were located at the benzenesulfona-
mide moiety, far from the free radical piperidin-N-oxide moiety.
On the contrary, in the presence of hCA II, the variation of the
EPR line shape indicates that the piperidine ring of the
inhibitor molecule, due to the binding to the enzyme, loses its
conformational freedom. Moreover, in agreement with the
corresponding CA II inhibition constants, the amount of
enzyme requested to reach the limit of the line shape was
markedly different for the three sulfonamides: the hCA II/
inhibitor ratio was highest for compound 44b (hCA II/
inhibitor >10 and KI of 165 nM),
175 and it did not change
much for the other two inhibitors (hCA II/inhibitor >0.7 and
Figure 22. View of the active site of the hCA IX/43h model showing
residues participating in the recognition of the inhibitor molecule. Zn2+
coordination and hydrogen bonds are also shown.
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2; KI of 12 and 41 nM for 44c and 44e, respectively).
175 EPR
experiments were carried out also in presence of hCA IX, using
two enzyme recombinant forms: the first consisted of the sole
catalytic domain and the second of the catalytic domain and the
proteoglycan (PG) fragment. This latter construct, representing
the in vivo extracellular part of the protein, was useful to detect
if the PG segment can modulate the interaction between the
inhibitor and the enzyme active site in cells. In both cases, it
was evident from the line-shape appearance, that the dynamics
of the N−O portion of the inhibitors were more hindered in
complexes with hCA IX than with hCA II, thus suggesting that
the hCA IX cavity was slightly smaller. The only difference
observed between the EPR spectra measured with hCA IX
catalytic domain alone and the longer recombinant form was
that a higher hCA IX/inhibitor ratio was necessary in the latter
case to reach the same EPR line shape. These results
demonstrated that the PG domain does not hinder the binding
of these molecules to the active site, although it can partially
limit the access.141 These data were successively confirmed by
the crystal structure resolution of the CA IX catalytic domain,63
which evidenced the location of the PG domain at the border of
the active site, thus justifying a partial steric hindrance in the
binding of bulky inhibitors. Altogether these data opened the
way to the development of new probes to be used for imaging
purposes by EPR techniques.
4.4.1.8. Benzenesulfonamides Derivatized with 129Xe-
Cryptophane Probes. Several investigations are currently
underway on 129Xe biosensors for their potential use as a
magnetic resonance imaging (MRI) agents. The monatomic
129Xe isotope has a spin −1/2 nucleus, exhibits a large chemical
shift window,176 and can be laser polarized to enhance MRI
signals ∼10000-fold,177 making it an appealing biomolecular
probe for MRI. Its current in vivo MRI applications are
restricted to functional lung imaging through the diffusion of
Xe gas;178 however, recent studies highlighted that encapsula-
tion of 129Xe within a cryptophane cage179 allows for its use as
biosensor that can be targeted to specific proteins using an
appropriate affinity tag.180,181
Chambers and co-workers applied these ideas to the design
of 129Xe-cryptophane biosensors able to bind to CA
isozymes.182 In these compounds a 129Xe binding cryptophane
was associated with linkers of different lengths to p-
benzenesulfonamide, yielding non diastereomeric biosensors
of type 45a−45c with dissociation constants for isoforms I and
II in the nanomolar range.182 The most interesting feature of
such compounds was that, when bound to the target enzymes
(in the reported studies, CA II), they showed reproducible
changes in 129Xe chemical shifts of 5.5, 7.5, and 5.0 ppm, for
45a−45c, respectively.182 It is worth noting that 7.5 ppm is the
largest chemical shift ever reported for a Xe biosensor.
Unfortunately, such compounds have not been evaluated for
their interaction with the tumor-associated isoforms, CA IX and
XII.
The structural details of the interactions with hCA II were
derived by reporting the crystal structure resolution of the CA
II/45c complex.162 This study showed the binding of the
benzenesulfonamide moiety to the Zn2+ ion of the active site,
and the bulky cryptophane moiety at the upper edge of the
cavity (Figure 24). Altogether these biochemical and structural
studies have provided the first experimental evidence of how an
encapsulated 129Xe atom can be targeted to a biomedically
relevant protein, offering very important perspectives in the
field of cancer diagnosis, although, as we have stressed above,
no data for the interaction of these compounds with CA IX and
XII have been provided so far.
Figure 23. Schematic representation of the binding mode of 44c
within hCA II active site (PDB code 3EFT). Residues participating in
the recognition of the inhibitor molecule are also reported.
Figure 24. Ribbon diagram of the hCA II/45c complex (PDB code
3CYU). The cryptophane-derived CA biosensor, the 129Xe atom, the
catalytic triad, the zinc ion and Thr199 residue are represented in ball-
and-stick.
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4.4.1.9. Hypoxia-Activatable Benzenesulfonamides. A
prodrug is a pharmacological substance, which is administered
in an inactive form, but can be metabolized in vivo into an
active metabolite, through a process termed bioactivation.183 In
the last years the employ of hypoxia-activatable prodrugs has
been largely exploited for improving the selectivity of tumor cell
killing.184 In particular, since, as reported above, hypoxic
tumors overexpress massive amounts of CA IX, this enzyme has
become a very interesting target for the design of hypoxia-
activatable CAIs.185−187 For this aim, different classes of
compounds have been developed,185−187 among which disulfide
derivatives of aromatic sulfonamides have shown the most
promising results (compounds of type 46a−46d and 47a−
47b).185,187 Such disulfide-containing sulfonamides are gen-
erally very bulky compounds and therefore unable to bind into
the CA active site cavity. However, they can be reduced under
the reducing conditions present in hypoxic tumors (see scheme
3), generating the corresponding thiol derivatives, which
present the classical features of the most potent CAIs. The
advantage in the use of this kind of molecules resides in the fact
that, even if the reduced thiol form of the inhibitor does not
present a high selectivity for isoform IX, since it is formed only
in the reduced environment of tumor cells, it should not inhibit
the other CA isoforms highly abundant in noncancer tissues.
N,N′-(2,2′-Dithio-dibenzoyl)bis-sulfonamide 47a is the mem-
ber of this class of bioreductive compounds better characterized
both from a functional and structural point of view.185 In its
oxidized form this molecule is a very weak CA inhibitor with
KIs values in the range of 653−4975 nM against CA I, CA II
and CA IX.185 However, when reduced to the corresponding
thiol derivative 48 (see Scheme 3), it becomes a good CA I
inhibitor (KI of 276 nM), and an optimal CA II and IX
inhibitor, with inhibition constants in the low nanomolar range
(16 nM and 9.1 nM for CA II and CA IX, respectively).185 The
molecular basis of the strong CA affinity of the reduced
derivative 48 was obtained from the analysis of the crystallo-
graphic structure of the CA II/48 complex.185 This structure
showed that, beyond the classical interactions of the
sulfonamide anchoring group, a large number of hydrophobic
interactions stabilize the organic scaffold of the inhibitor in the
CA active site. In particular, the aminocarbonylbenzenesulfo-
namide moiety establishes strong van der Waals interactions
with residues Asn67, Gln92, Val121, Phe131, Leu198, Thr199,
Thr200, Pro201, and Pro202 (Figure 25A), while the aromatic
thiol substituent interacts poorly with the enzyme, as confirmed
by its rather disordered electron density.185 Molecular
modeling studies on the corresponding adduct with CA IX
have revealed that the higher affinity of the molecule for CA IX
with respect to CA II could be explained thanks to an additional
polar interaction between enzyme residue Gln67 and the thiol
group of the inhibitor (Figure 25B).185 In vivo experiments on
some representative elements of such class of compounds are
currently under way to test their antitumor activity.
Scheme 3. Reduction of Disulfide-Containing Sulfonamides
to the Corresponding Thiol Derivatives
Figure 25. (A) Representation of 48 binding to (A) hCA II (PDB
code 2HD6) and (B) hCA IX (obtained by modeling studies). Zn2+
coordination, hydrogen bonds and residues participating in inhibitor
recognition are also shown.
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4.4.2. Thiophene, Thiadiazole, and Thiadiazoline
Derivatives. Heterocyclic sulfonamides are among the most
studied CAIs. The interest in this class of molecules started in
1945 when the pioneering studies of Davenport reported that
thiophene-2-sulfonamide 49 was 40 times more active than
sulfanilamide 5 as CAI.188 Starting from this observation a large
number of sulfonamides incorporating a range of heterocyclic
rings (such as alkyl and aryl imidazoles, benzimidazoles,
benzothiazole, thiazole, pyrazine, etc.) was reported and tested
for CA inhibitory properties.189,190 These studies allowed to
derive the following general considerations: (i) sulfonamides
containing five-membered rings were usually more efficient as
CAIs than those containing six-membered rings; (ii) the
presence of nitrogen and sulfur atoms within the ring was
associated to better CA inhibitory properties. Indeed, 5-
substituted-1,3,4-thiadiazole-2-sulfonamide 50, 6-substituted-
benzothiazole-2-sulfonamide 51, and 1,3,4-thiadiazoline-2-
sulfonamides 52 were demonstrated to act as particularly
efficient inhibitors. Good inhibitory properties were also shown
by derivatives of thiophene-2-sulfonamide 53 with different
substitution patterns.191 Finally, sulfonamide derivatives in-
corporating the bicyclic thieno-thiopyran ring (54 and 55),
which were used as lead compounds for the development of the
first clinically used, topically acting antiglaucoma sulfonamides,
dorzolamide 56 and brinzolamide 57, behaved as effective CAIs
against a range of isoforms, among which CA II, IX, XII,
etc.2,13,192
Thiadiazole, thiadiazoline and thiophene derivatives of type
(50, 52, and 53) are among the most structurally studied
heterocyclic sulfonamides. Indeed, a very large number of
crystallographic structures of adducts of such molecules with
hCA II has been reported.193−197 These studies showed that,
independently on the nature of the R substituent, the
heterocyclic sulfonamide moieties of these inhibitors are rather
well superimposable when bound to the enzyme active site,
with only very small differences in the ring orientation. Figure
26 summarizes the interactions that such inhibitors can
establish within the hCA II active site. It can be seen that in
addition to the canonical Zn2+ coordination of the sulfamoyl
moiety, the organic scaffold of all these molecules establishes
van der Waals interactions with residues Gln92, Val121,
Leu198, Thr199, and Thr200.193−197 Moreover, the thiadiazole
ring, differently from the thiophene and thiadiazoline scaffolds,
can also participate to a hydrogen bond interaction with the
Thr200OG1 atom (Figure 26B).193,195−197 Varying the nature
of the R group in thiophene, thiadiazole, and thiadiazoline
derivatives (see as examples compounds 58−69), a large
number of compounds was obtained, which significantly differ
in their affinities for various CA isoforms, and in their
physicochemical properties.118,189−191,196,198−203 As an exam-
ple, acetazolamide 58, one of the most studied CAIs, has been
obtained by the derivatization of the exocyclic amino moiety
substituting C5 of the 1,3,4-thiadiazole ring with an acetyl
group.193,204,205 This compound, which was shown to possess
very good pharmacological properties, after its discovery in
1954, has been widely used for the treatment of edema,
glaucoma, gastroduodenal ulcers, mountain sickness, and many
other neuromuscular disorders.204,205
Among the thiadiazoline derivatives one should mention
methazolamide 61, a compound that has been, and it is still
used, as antiglaucoma drug for more than 40 years.6 Thanks to
its excellent pharmacological properties, it has been also utilized
as lead compound for the design of many CAIs.146,198,200,202
Among these, derivatives incorporating fluorinated tails (see as
examples compounds 62 and 63)202 are of particular interest
since, beyond showing a very strong in vitro affinity (in the low
nanomolar range) for the critically relevant isozymes involved
in aqueous humor secretion within the eye, that is, CA II and
CA IV/XII, they possess a good water solubility and a rather
high lipophilicity.202 As a consequence, they have been easily
formulated as eye drops at physiological pH values and their in
vivo efficacy, tested in animal models of glaucoma, is much
Figure 26. Schematic representation of the binding mode of (A) thiophene, (B) thiadiazole, and (C) thiadiazoline derivatives within hCA II active
site.
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higher than that of the topically acting antiglaucoma agents
dorzolamide 56 and brinzolamide 57.
4-Methyl-5-perfluorophenylcarboximido-δ2-1,3,4-thiadiazo-
line-2-sulfonamide 63 is one of the most interesting
compounds of this series. Indeed, it possesses a hCA II
inhibitory activity almost 10 times higher (KI of 1.5 nM) than
its precursor, methazolamide 61 (KI of 14 nM) and has been
shown to act as an efficient topically acting antiglaucoma
agent.202 The crystallographic structure of its adduct with hCA
II was utilized to derive the molecular factors that can explain
the enhanced affinity of this type of fluorinated compounds for
the CA active site. In particular, the analysis of the structure
showed that the binding mode of 63 to hCA II maintains the
same features of other heterocyclic sulfonamides for what
concerns the thiadiazolinesulfonamide moiety, but differs when
the perfluorobenzoylimino fragment is considered. Indeed, this
tail makes a hydrogen bond with the side chain of residue
Gln92 and a strong face-to-face stacking interaction with
Phe131 (Figure 27).194
The derivatization of the C5 atom of the thiophene-2-
sulfonamide or 1,3,4-thiadiazole-2-sulfonamide scaffolds with a
tail containing a second sulfonamide moiety, generating
compounds of type 60 and 65−69,195−197 has also been widely
used to obtain CAIs with improved physicochemical proper-
ties.196,200 Benzolamide 65 is an interesting example of this
kind of derivatization.200,206 This molecule presents peculiar
physicochemical properties. Due to the presence of the second,
highly acidic sulfonamide moiety (pKa of 3.4),
206 it is much
more polar than the structurally related analogue 58, and
consequently crosses biological membranes much more
difficultly as compared to other CAIs in clinical use.5,200,206
To modify the hydrophilic character and the lack of water/lipid
solubility of 65, some derivatives incorporating polyhalophe-
nylsulfonamide moieties instead of phenylsulfonamide were
investigated (see compound 60 as an example).118,202,207 These
compounds generally retained the excellent inhibitory proper-
ties of the lead compound, but at the same time possessed
much higher solubility both in water and in organic solvents, as
well as better penetrability through biological membranes.197
Several structural studies on the complexes that these
heterocyclic bis-sulfonamides form with hCA II are so far
available. Such studies have shown that the second sulfonamide
group can help to improve the binding affinity, establishing
several direct or solvent-mediated polar interactions with active
site residues.195−197
Further modifications of the thiophene disulfonamides 67−
69 can be obtained connecting the secondary sulfonamide
group with the C4 atom of the thiophene ring, leading to
bicyclic compounds containing the thienothiazine-6-sulfona-
mide-1,1-dioxide skeleton (compounds 70−79).196 The CA
inhibitory properties of these molecules were investigated in
detail by Boriack-Sjodin and co-workers, showing that they
generally present an enhanced enzyme−inhibitor affinity with
respect to the corresponding noncyclized thiophene disul-
fonamides.196 Structural studies suggested that the increase in
binding affinity after cyclization could be ascribed to the
preorganization of the secondary sulfonamide in an orientation
that allows to optimize the edge-to-face interaction of its
aromatic substituent with residue Phe131 (Figure 28).196 The
effect of several modifications of the thienothiazine-6-
sulfonamide-1,1-dioxide scaffold was also investigated by
means of a combined kinetic and structural approach.196 As
an example, to analyze the effects of stereochemical and
configurational variations at the C4 position of the bicyclic
scaffold, kinetic and structural investigations were conducted on
compounds 70−72. These studies showed that the addition of
a methylamino group with R stereochemistry (compound 70)
slightly changes the orientation of the thiophene ring with
respect to the compound without the C4 substituent (71)
(Figure 29). This change does not lead, however, to dramatic
consequences on the binding affinities of these compounds for
Figure 27. Active site of hCA II/63 complex showing the zinc ion
coordination, hydrogen bonds and residues participating in the van der
Waals interactions with the inhibitor scaffold (distance <4.5 Å). The
PDB coordinate file has been kindly provided by Claudiu T. Supuran.
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the enzyme. On the contrary, the introduction of a
methylamino moiety with S stereochemistry (compound 72)
causes a highly significant change in the orientation of the ring
(see Figure 29) and determines a dramatic reduction in CA II
binding affinity. These studies clearly indicate that thienothia-
zine-6-sulfonamide-1,1-dioxide derivatives having substituents
with S stereochemistry at C4 cannot be easily accommodated in
the CA II active site. In agreement with this observation, when
a racemic mixture of the inhibitor is used, only the R
enantiomer binds to the enzyme.196 The insertion of an
additional degree of unsaturation between C3 and C4 in the
six-membered thiazine ring, as observed in compound 75, does
not alter the binding mode of the inhibitor.196 On the contrary,
the introduction on this skeleton of a substituent in position 3,
as observed in compounds 76 and 77, has a striking effect on
the inhibitor binding mode.208 In particular, the orientation of
the aromatic substituents on the endosulfonamide nitrogen
inside the active site changes dramatically. In fact, in the crystal
structure of the hCA II/76 complex, the morpholino group is
associated with the hydrophobic patch defined by Phe131,
Val135, Leu198, Pro202, and Leu204, which is instead
occupied by the aromatic substituent on the endosulfonamide
nitrogen in the absence of a C3 substituent (Figure 30).
Consequently, this latter is oriented toward the opposite side of
the active site, interacting with residues Asn67, Ile91, Gln92,
and Phe131 (Figure 30).208 The effect of the substitution of the
aromatic substituents on the endosulfonamide nitrogen with
aliphatic ethers, such as in 78, 79, and brinzolamide 57, was
also carefully examined.196,208 These studies revealed that the
loss of the edge-to-face interaction between the aromatic
substituent and Phel31 had a minor impact on enzyme−
inhibitor affinity, as long as the aliphatic substituent group was
sufficiently long to desolvate a correspondingly large hydro-
phobic patch in the enzyme active site.
The thienothiopyran ring is another bicyclic scaffold derived
from thiophene, which has been widely investigated for the
development of potent CAIs. Representative examples of CAIs
containing this scaffold are the topically acting antiglaucoma
drug dorzolamide 56 and its strictly related analogues 80−81,
which differ from each other only in the length of the
substituent on the 4-amino group: 80, proton, 81, methyl and
56, ethyl. The binding affinity of these molecules for hCA II, as
well as the three-dimensional structures of the corresponding
complexes, were investigated209 allowing to derive some
Figure 28. View of the binding of 73 to hCA II active site (PDB code
1BNT). Zn2+ coordination, hydrogen bonds and hydrophobic
interactions of the inhibitor molecule (distance <4.5 Å) are also
shown.
Figure 29. Superposition of hCA II/inhibitor adducts: 70 is reported
in blue (PDB code 1BNM), 71 in yellow (PDB code 1BNN), and 72
in red (PDB code 1BNV). The figure shows the variable orientation of
the thienothiazine-6-sulfonamide-1,1-dioxide scaffold resulting from
substitutions at the inhibitor C4 atom.
Figure 30. Structural superposition between hCA II/75 (orange, PDB
code 1BN3) and hCA II/76 (blue, PDB code 1I91), showing the
different orientations of the substituents on the endosulfonamide
nitrogen.
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important structure−function relationships for this subclass of
compounds. In particular, kinetic studies showed that 80 and
81 present identical hCA II binding constants (within the
experimental error), whereas 56, despite the high similarity in
chemical structure, shows a binding affinity 4−5 times
higher.210 These findings have been well rationalized by solving
the crystallographic structures of the corresponding complexes.
Indeed, the analysis of such structures showed that 56, 80 and
81 adopt a very similar conformation and orientation within the
hCA II active site. The only differences observed in these
complexes concern the position of the His64 side chain. In
particular, in the hCA II/80 and hCA II/81 adducts, the His64
side chain is observed in its in conformation,209 while in the
hCA II/56 complex it is forced in its out conformation by the
presence of the bulkier 4-aminoethyl group, with the
consequent release of a water molecule to the bulk solvent.209
These findings suggest that the increase in entropy, caused by
the release of the bound water molecule, plays a key role in
determining higher hCA II affinity of 56 with respect to 80 and
81, and open new perspectives on the factors that should be
considered in the design of even more potent CAIs.
Finally, it should be also mentioned that the dorzolamide
scaffold has also been recently used for the design of new
bifunctional compounds of type 82−86, which beyond to act as
CAIs, contain a nitric oxide (NO)-releasing moiety.211 NO
donors are a relatively underexplored class in the field of ocular
drugs, despite the presence of NO target in all eye
compartments.212 It has been observed that hypertensive
glaucoma patients have a decreased NO/cGMP content in
the aqueous humor,213 moreover some NO donors have been
shown to decrease intraocular pressure in normal and
pathological conditions.214−216 For this reason the develop-
ment of NO-donating CAIs for topical administration
represents an interesting alternative to the classical antiglauco-
ma drugs.211 Accordingly, in vivo experiments showed that
compounds 82 and 83 were able to induce potent intraocular
pressure lowering effects in normotensive rabbits, anticipating
their potential use for the treatment of glaucoma.211
4.4.3. Sulfonamides Containing Other Ring Systems.
Several other annulated bicyclic sulfonamides, different from
those derived from thiophene, described in the previous
paragraph, have been investigated as CAIs. Many of these
derivatives, such as indanesulfonamides 87 and 88, the
thiazolinone derivative 89, indolesulfonamide 90, the thiaben-
dazole derivative 91 and the 1,2,3,4-tetrahydroisoquinoline
derivative 92, have been also structurally characterized in their
adducts with hCA II.217−222 The indolesulfonamide 90 is a
particularly interesting representative of this type of compounds
due to its peculiar CA inhibitory properties.219 Indeed, CA
inhibition assays against all human isoforms showed that this
molecule is a medium potency inhibitor of CA VII, IX, XII, and
XIV (KI values in the range of 48−110 nM), whereas it strongly
inhibits hCA I and II (KI values of 7.5 and 7.2 nM for hCA I
and II, respectively),219 thus demonstrating a slight selectivity
for hCA I and hCA II with respect to the other isoforms. The
selectivity for hCA I is a particularly interesting feature,
considering that only few potent hCA I inhibitors have been
reported so far13,14,16,204 and in view of the recent observations
of Feener’s group, which reported that substantial levels of hCA
I were identified in the vitreous of patients with diabetic
retinopathy. Thus, the inhibition of this isozyme could provide
new opportunities for the treatment of this pathological
condition.28 The unusual inhibition profile of 90, combined
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with its peculiar chemical structure, characterized by the
presence of a hydrazide moiety in position 2 and a phenyl
substituent in position 3, suggested the possibility to utilize this
molecule as lead compound for the design of isoform selective
CAIs. For this aim the crystallographic structure of the adduct
of 90 with hCA II was solved, offering additional hints for a
structure based drug design.219 The analysis of this structure
showed that the sulfonamide group classically binds to the zinc
ion, the indolesulfonamide scaffold fills the bottom of the active
site establishing a large number of hydrophobic interactions,
while the hydrazide moiety participates in a network of
hydrogen bonds with residues Asn62 and Asn67 (Figure 31A).
However, the most interesting data from the drug design point
of view was the observation that the 3-phenyl group of 90 is
accommodated in a sort of pocket within the active site, where
enough additional space is available for various moieties to be
introduced as substituents to the phenyl ring (Figure 31B).
Thus using this X-ray crystal structure as starting point, the
design and synthesis of a series of 2-(hydrazinocarbonyl-3-
substituted-phenyl)-1H-indole-5-sulfonamides, of type 93, were
reported.223 Kinetic experiments performed against all the
catalytically active CA isozymes showed that these molecules
presented kinetic properties different from those of their lead
compound 90. Indeed, they were not anymore selective for
hCA I, but presented excellent, low-nanomolar inhibition of
hCA II and hCA XIV,223 showing that the substitution of the 3-
phenyl moiety can have dramatic consequences on the
inhibition profile of such molecules. Altogether these studies
indicated the indolesulfonamide scaffold as an interesting
alternative to the classical benzenesulfonamides for obtaining
CAIs, whose properties can be efficiently modulated by
changing the nature of the substituent in the 3-position of
the indole ring.223
The thiabendazole molecule 94, a broad-spectrum anti-
helmintic drug used both for the treatment of parasitic
infections in animals and humans and as an agricultural
fungicide,224,225 possesses a byciclic scaffold structurally related
to that of 90. Few data are at present available on the
mechanism of action of this molecule, which seems to be
correlated to its selective binding to the parasite β-tubulin, with
subsequent prevention of microtubule formation.226 Given that
the widespread resistance to many clinically used drugs for the
treatment of helminthic infections represents a global health
problem, it is very important to design such new pharmaco-
logical agents. In this scenario, the parasitic CAs could
represent a new target for the development of a novel clinical
strategy. With this aim, a thiabendazole derivative incorporating
a sulfonamide functionality (compound 91) was synthesized.220
On the basis of the design hypothesis, this molecule, besides
the original antihelminthic activity, had to possess the ability to
bind to the CA active site, because of the presence of the
sulfonamide group. Indeed, inhibition assays performed both
on the CAH-4b, a CA isozyme isolated from the worm
Caenorhabditis elegans, and on the mammalian CA I-XIV,
indicated that this derivative strongly inhibited CAH-4b (KI
value of 9.35 nM) and also acted as potent inhibitor of isoforms
hCA I, IV, VB, VI, IX, and XII (KI values in the range of 6.4−
50.9 nM).220 The binding mechanism of 91 to the CA active
Figure 31. (A) Schematic representation of hCA II/90 (PDB entry
3B4F) active site. (B) Solvent accessible surface of hCA II showing the
inhibitor 90 accommodated within the active site channel.
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site was elucidated by the analysis of its X-ray structure in
complex with hCA II, showing that 91 presents the canonical
coordination of the Zn2+ ion by means of the sulfonamide
moiety, with the benzimidazole scaffold filling the active site
channel of the enzyme and participating in several hydrophobic
contacts with the enzyme and into a π−π stacking interaction
with Phe131. Interestingly, the comparative analysis of this
thiabendazole derivative with compound 90 reveals that the
arrangement of their indole/benzimidazole moieties within
hCA II active site is completely different, despite the high
similarity of their chemical structure. Indeed, the bicyclic
scaffolds of the two inhibitors are tilted by almost 90° with
respect to each other (Figure 32). This different orientation
could be ascribed to the different substitution pattern of these
two bicyclic systems, highlighting once again that the nature of
the substituents on such scaffolds can significantly modulate the
binding mode to the enzyme and consequently the binding
affinity.220
4.4.4. Thiazide Diuretics. Thiazide diuretics represent a
class of pharmacological agents widely used for the treatment of
hypertension, which exert their action by promoting sodium
chloride (and osmotically obligated water) excretion in
different segments of nephron.227 They have been the first
well-tolerated antihypertensive drugs that significantly reduced
cardiovascular disease morbidity and mortality in placebo-
controlled clinical studies,227−234 and still represent an
important therapeutic option in patients with cardiovascular
diseases, but also for those suffering type II diabetes, obesity,
and related metabolic complications.227,229−234
This class of molecules includes derivatives of benzothiadia-
zine 95, but also compounds which present a similar
pharmacological action, but do not incorporate the thiazide
scaffold. The latter compounds are properly termed thiazide-
like diuretics. Trichloromethiazide 96, chlorthalidone 97,
indapamide 98, and metolazone 992,5,13,17 are among the best
known members of this class of agents. These compounds share
several structural features, such as the presence of a SO2NH2
moiety attached to a chloro-benzene scaffold, with the halogen
atom in ortho to the sulfamoyl group, as well as various bulky
groups substituting the aromatic scaffold. Right from the start
the presence of a primary SO2NH2 group suggested that these
compounds could also act as CAIs; however, when they were
first launched, in 60s or 70s, only CA isozymes I and II were
known. This is the reason for which the interaction of such
diuretics with all catalytically active CA isoforms has been only
recently investigated.235−238 The corresponding inhibition data,
obtained by means of a stopped-flow assay, showed that these
compounds behave as weak inhibitors of isozyme II, usually in
the micromolar range,235−238 while they considerably inhibit
other isozymes, known nowadays to be involved in critical
physiological processes (see Table 3). Crystallographic studies
also confirmed the interaction of this class of compounds with
the CA active site. In particular, the X-ray structures of the
adducts of three of these thiazide diuretics (96−98) with hCA
II were reported,235−237,239 showing that these inhibitors
present a rather similar binding mode to the enzyme active
site (Figure 33A,B,C). Indeed, in all complexes the tetrahedral
geometry of the zinc ion and the hydrogen bond network
involving the inhibitor sulfonamide moiety and amino acid
residues from the enzyme active site were observed.53,235−239
The sulfamoyl-chlorophenyl fragments of these three sulfona-
mides were well superimposable with each other (see Figure
33D), making several favorable van der Waals interactions.
However, significant differences, which could explain the
different binding affinity toward CA II of these structurally
related compounds, were observed in the orientation of the
remaining part of the 96−98 scaffolds. As a consequence of
these different orientations, the tails of 96 and 97 were
stabilized by several hydrogen bond interactions (Figure
33A,B), while the tail of 98 was stabilized only by van der
Waals contacts (Figure 33C).235−239
Altogether these kinetic and structural studies demonstrated
the capability of thiazide diuretics to efficiently interact with the
active site of several CA isoforms. This is a rather interesting
result considering the wide clinical use of such compounds.
Indeed, it is tempting to speculate that the inhibition of the
CAs, present in blood vessels or in the kidneys, could be
responsible in some way for additional therapeutic effects of
these drugs or for some of their side effects, such as the recently
Figure 32. Superposition of the hCA II/inhibitor adducts: 90 is
reported in red (PDB entry 3B4F) and 91 in blue (PDB entry 3FFP).
Zn2+ coordination and hydrogen bonds of the sulfonamide moiety are
also shown. The enzyme is represented as ribbon diagram.
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observed protective role of indapamide against ischemia-
induced injury and dysfunction of the blood−brain barrier,230
or its organ-protective effect in animal models of renal
failure.233,234 However, no specific biochemical or pharmaco-
logical studies to prove these hypotheses are available so far.
Further studies in this field could thus offer novel therapeutic
applications of such compounds. It should be also mentioned
the low nanomolar inhibitory action of some of these
sulfonamides against isoforms involved in important patholo-
gies, such as CA IX and XII (cancer and metastases) or CA VII
(epilepsy).238 However, detailed in vivo studies for establishing
alternative uses of these compounds are lacking for the
moment.
4.4.5. Aliphatic Sulfonamides. A dogma in the CA drug
design was that aliphatic sulfonamides with general formula R-
SO2NH2 (R= Me, PhCH2) were inactive as inhibitors,
differently from the aromatic/heterocyclic ones of the type
Ar-SO2NH2.
6 This view was subsequently challenged,240 being
Table 3. Inhibition Data of the Thiazide Diuretics 96−99 against CA Isoforms I-XIVa
KI (nM)
isozymeb 96 97 98 99
hCA Ic 345 348 51900 54000
hCA IIc 91 138 2520 2000
hCA IIIc 5.6 × 105 1.1 × 104 2.3 × 105 6.1 × 105
hCA IVc 449 196 213 216
hCA VAc 763 917 890 750
hCA VBc 134 9 274 312
hCA VIc 2459 1347 1606 1714
hCA VIIc 7.9 2.8 0.23 2.1
hCA IXd 87 23 36 320
hCA XIId 312 4.5 10 5.4
mCA XIIIc 645 15 13 15
hCA XIVc 3450 4130 4950 5432
aData were obtained from refs 236 and 237. bh = human, m = murine isozyme. cFull length enzyme. dCatalytic domain.
Figure 33. View of the binding mode of (A) 96 (PDB code 1ZGF), (B) 97 (PDB code 3F4X), and (C) 98 (PDB code 3BL1) to hCA II active site.
Zn2+ coordination, hydrogen bonds and hydrophobic interactions (distance <4.5 Å) stabilizing the inhibitors are also reported. (D) Superposition of
hCA II-inihibitor structures: 96 is colored in blue, 97 in salmon, and 98 in white. hCA II is represented as ribbon diagram.
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shown that aliphatic sulfonamides incorporating perhaloalkyl
moieties of the type CnX2n+1SO2NH2 (n = 1−4, X = F, Cl)
potently inhibit several CA isozymes. Consequently, this type
of compounds has become object of great interest in the search
of molecules with improved selectivity/inhibition profiles as
compared to the classical aromatic/heterocyclic sulfonamide
CAIs. However, only little structural information is available so
far on their binding mode to the CA active site.
The first aliphatic sulfonamide to be structurally charac-
terized in complex with hCA II was trifluoromethane
sulfonamide 100.241 This compound showed significant CA
inhibitory properties, mainly attributable to the strong acidity
caused by the presence of the strongly electron withdrawing
CF3 moiety in close proximity to the sulfonamide group.
241
The structural analysis of the CA II/100 complex showed that
the binding mode of this inhibitor to the CA active site was
considerably different from that of classical aromatic/
heterocyclic sulfonamides. Indeed, differently from bulky
aromatic groups of aromatic/heterocyclic sulfonamides, which
generally point toward the external part of the active site cleft
(Figure 34), the small hydrophobic trifluoromethyl moiety was
oriented inward into the active site, making strong van der
Waals contacts with residues Val121, Val143, Leu198, Thr199,
and Trp209. This different orientation caused also a rearrange-
ment of the sulfonamide group, which was rotated by about
180° around the sulfur−nitrogen bond, with respect to the one
present in aromatic/heterocyclic sulfonamides (Figure 34).240
Compounds of type 101−104, including the widely used
antiepileptic drug zonisamide 101,242−244 represent a different
type of aliphatic sulfonamide, characterized by the presence of a
heteroaromatic ring connected to the sulfonamide moiety
through an aliphatic spacer. X-ray crystallographic studies of
adducts of these inhibitors with hCA II highlighted that,
although these compounds have a similar organic scaffold, they
present significant differences in their binding mode to the
enzyme (Figure 35). Indeed, while the heterocyclic rings of
101−103 are rather well superimposable, all of them being
oriented toward the hydrophobic part of the active site (Figure
35A,B,C),242−244 104 presents a completely different orienta-
tion, being found toward the hydrophilic region, as a
consequence of a π-stacking interaction with the imidazole
ring of His94 (Figure 35D).244 This peculiar orientation is
probably caused by the formation of a strong hydrogen bond of
the −CF2- linker with the Thr200OG1 atom. A further
hydrogen bond interaction between the NH2 group of the
inhibitor and the Asn67OD1 atom contributes to the
stabilization of the adduct (Figure 35D).
Interestingly, a detailed comparison of the CA binding mode
of 101−104 with structurally related heterocyclic sulfonamides,
such as acetazolamide 58, revealed that, when bound to the
enzyme, all these molecules conserve the tetrahedral geometry
of the zinc ion and the hydrogen bond network between the
sulfonamide moiety and the enzyme active site.242−244
Nevertheless, they present a completely different orientation
of the heterocyclic ring (Figure 36). In fact, the presence of the
aliphatic spacer in compounds 101−104 introduces an
additional rotational freedom between the sulfonamide and
the ring moiety allowing orientations inside the active site not
accessible to the classical heterocyclic CAIs. These studies
highlighted novel binding modes of aliphatic sulfonamides,
suggesting that these compounds can represent an interesting
alternative to the classical aromatic/heterocyclic sulfonamides
in the development of CA isoform-selective inhibitors.
4.5. Sulfamates and Sulfamides
As outlined in the previous paragraphs, the presence of a zinc-
binding group (ZBG) in the scaffold of the CAIs directly
interacting with the metal ion present within the enzyme active
site is one of the main factors influencing inhibitory activity.
The classical ZBG for the design of CAIs is the unsubstituted
sulfonamide.2,12−15,53,114 The most obvious bioisosteres of this
group are the sulfamate and sulfamide ones, in which an
additional electron-withdrawing atom/group (O or NH,
respectively) is directly attached to the sulfamoyl function,
generating compounds with general formula R−O−SO2NH2 or
R−NH−SO2NH2. However, only relatively later after the
sulfonamides started to be used clinically,6 these two groups of
derivatives were considered as interesting candidates for
obtaining CAIs. The first report on sulfamates as CAIs was
from Maren’s group245 and from Maryannof et al.246
Subsequently Supuran’s group showed in 1996247 that the
simple sulfamide 105 and sulfamic acid 106 bind to the metal
ion in the Co2+-substituted CA II, whereas the X-ray structures
of these two simple compounds in adduct with CA II have been
reported several years later.108 Such structures showed that
these two molecules were able to participate in a more intricate
hydrogen bond network than that formed by the classical
sulfonamide inhibitors, due to the presence of the additional
oxygen/nitrogen atom (Figure 37).108 Nowadays there are a
large number of aromatic, heterocyclic, aliphatic and sugar-
Figure 34. Structural superposition between hCA II/100 (yellow,
PDB code 1BCD) and hCA II/benzenesulfonamide 6 (red, PDB code
2WEJ) showing the different orientation of the inhibitors within hCA
II active site. The enzyme is represented as a surface-model and the
catalytic zinc ion as a sphere.
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based sulfamates and sulfamides which were shown to possess
highly effective inhibitory properties against all known
mammalian isoforms.2 Thus, sulfamates and sulfamides
constitute a highly important class of CAIs, with some
derivatives (i.e., topiramate) clinically used for the treatment
of epilepsy and obesity.20−22,25,248
4.5.1. Aliphatic Sulfamates. Mono- and bis-aliphatic
sulfamates are an interesting class of CAIs, which potently
inhibit several CA isozymes. Recently new compounds
belonging to this class, that is, 107−110, were characterized
Figure 35. Active site representation of hCA II in complex with (A) 101,242 (B) 102 (PDB code 3BL0), (C) 103 (PDB code 2EU2), and (D) 104
(PDB code 2EU3). Zn2+ coordination, hydrogen bonds and residues participating in van der Waals interactions are also shown. Water molecules are
indicated as red spheres.
Figure 36. Superposition of hCA II/inhibitor adducts showing the
different orientation of aliphatic sulfonamides from the classical
heterocyclic ones. Acetazolamide 58 (PDB code 1ZSB) is reported in
red, 102 in cyan, and 104 in orange; hCA II is represented as ribbon
diagram.
Figure 37. Schematic representation of the binding mode of (A)
sulfamide 105 and (B) sulfamate 106 to hCA II active site. Zn2+
coordination and H-bond interactions stabilizing inhibitor molecules
are also reported.
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both structurally and kinetically.249−252 Kinetic studies showed
that these compounds were nanomolar inhibitors of only a few
isoforms, namely, hCA II, IX and XII, unlike aromatic/
heterocyclic sulfonamides in clinical use which promiscuously
inhibit with low nanomolar affinity most CA isozymes (Table
4). Moreover, the bis-sulfamates showed higher affinity for the
tumor-associated isozyme CA IX compared to hCA II, whereas
the opposite was true for the corresponding monosulfamates
(Table 4). Crystallographic and molecular modeling studies252
helped to rationalize this result. In particular, the X-ray crystal
structures of the adducts of 108 and 110 with hCA II were
solved (Figure 38A,B) and then used as template to build the
models of the corresponding hCA IX complexes (Figure
38C,D). The comparison of hCA II/108 and hCA IX/108
adducts showed that while the Zn2+ binding site and the key
hydrogen bonds between the sulfamate moiety of the inhibitor
and the enzyme active site were preserved in both complexes,
different patterns of van der Waals and/or hydrogen bond
interactions, established by the inhibitor tail, were observed.
Indeed, the hCA II/108 complex was stabilized by a number of
van der Waals interactions between the inhibitor alkyl moiety
and the hydrophobic residues lying on the short helical region,
defined by amino acid residues 130−135, and the loop
incorporating residues 198−204 (Figure 38A). These inter-
actions were not conserved in the corresponding hCA IX
complex, accounting thus for the lower affinity of the inhibitor
toward hCA IX than for hCA II. In particular, the van der Waals
interactions involving Leu204 were drastically attenuated in the
hCA IX adduct not only by the replacement of the Leu bulky
residue with the smaller alanine, but also by the concurrent
mutation of Val135 into a Leu (Figures 2 and 38C). In fact,
Ala204 in hCA IX, similarly to its counterpart Leu204 in hCA
II, is located on the re-entrant side of the loop 198−204,
forming a sort of “gate” with residue Leu135, located at the end
of the helix. This gate is narrower in hCA IX than in hCA II due
to the Val/Leu mutation, thus hampering the access to the
inhibitor alkyl moiety. The mutations Phe131/Val and Gly132/
Asp also play a key role in lowering the affinity of the inhibitor
toward hCA IX with respect to hCA II. In fact, in the first case
the shorter side chain of the valine residue weakens the van der
Waals interaction with the inhibitor while in the second one,
where a neutral residue is substituted by a negatively charged
one, a potential destabilizing effect on its interaction with the
inhibitor hydrophobic tail was observed. On the contrary, this
last mutation determines the higher affinity of compound 110
toward hCA IX. In fact, the second sulfamate group of the
inhibitor, which in the adduct with hCA II forms only
hydrophobic contacts (Figure 38B), in hCA IX is engaged in a
hydrogen bond interaction with the aforementioned Asp132
residue (Figure 38D). This additional hydrogen bond balances
the less favorable van der Waals interactions occurring in the
hCA IX/110 complex with respect to the hCA II/110 adduct
and is responsible for the inversion observed in the affinities of
compounds 108 and 110 for the two isoforms.252
Table 4. Inhibition Data of Sulfamates 107−110 against CA
Isoforms I−XIV, by a Stopped-Flow CO2 Hydrase Assaya
KI (nM)
isozymeb 107 108 109 110
hCA Ic 3.7 530 378 890
hCA IIc 2.6 0.7 14.6 24.5
hCA IIIc 9100 877 1128 1206
hCA IVc 79.9 67.6 84.1 91.2
hCA VAc 1254 805 1202 1368
hCA VBc 624 888 1457 1592
hCA VIc 795 1334 1020 1414
hCA VIIc 76.6 88.9 79.6 92.3
hCA IXd 25.0 23.1 4.0 7.0
hCA XIId 7.0 7.9 7.9 8.2
mCA XIIId 1125 956 569 960
hCA XIVc 390 711 605 852
aData were obtained by ref 252. bh = human, m = murine isozyme.
cFull length enzyme. dCatalytic domain.
Figure 38. Representation of hCA II active site in complex with (A)
108 (PDB code 3IBU) and (B) 110 (PDB code 3IBN). The panels
(C) and (D) show the corresponding adducts of 108 and 110 with
hCA IX obtained by a homology modeling study. The ribbon diagram
of the helical region 130−135 is also shown.
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Altogether these findings seem to indicate the region
incorporating amino acid residues 130−136 as a “hot spot”
to be considered in structure-based drug design of CA IX-
selective inhibitors. Indeed, major differences in such residues
present in the tumor-associated isoform compared to the
cytosolic ones were evidenced, in addition to different
interactions in which the tails of the inhibitors participate.252
4.5.2. Sulfamate CAIs Also Acting as Steroid Sulfatase
and Aromatase Inhibitors. Steroid sulfatase (STS)253,254
represents a rather new therapeutic target for the treatment of
hormone-dependent breast cancer, since it is involved in the
production of estrogenic steroid hormones which promote the
growth and development of this type of cancer. For this reason
several STS inhibitors have been developed in the last years,
most of which have an aryl sulfamate ester as their active
pharmacophore.253 The presence of a sulfamate group in such
molecules confers them the capability to interact simulta-
neously also with CA active site. This has a double effect: on
one hand, the interaction with hCA II, which is highly express
in red blood cells, is believed to improve the oral bioavailability
and pharmacokinetics of such molecules, and to provide a
protection against first pass metabolism.255 On the other hand,
the interaction with hCA IX,249 whose expression is increased
in many tumors, suggests that the overall anticancer efficacy of
this class of drugs could be due to the simultaneous inhibition
of this enzyme. Consequently in the last years, many X-ray
structures of these compounds in complex with hCA II have
been reported, in order to investigate in detail the interaction of
sulfamate-based STS inhibitors with CAs.256−263
The steroid sulfamates were among the first type of STS
inhibitors discovered. Among them, estrone 3-O-sulfamate
(EMATE) 111, reported by Potter’s group in 1994, is one of
the most potent STS inhibitors.264 However, this compound
was shown to be extremely estrogenic in rodents, and thus not
adapted for clinical development.265 Several alternative
approaches were thus utilized to develop EMATE analogues,
devoid of these side effects. Among these approaches it should
be mentioned the development of nonsteroidal analogues,
which led to the tricyclic 667-coumate 112, an STS inhibitor
currently in phase I clinical trials for the treatment of breast
cancer,254,257,266−268 as well as the modification of the EMATE
scaffold and/or its substituent pattern, to give derivatives of
type 113−118.257,259−261,263,269,270 The X-ray crystal structures
of the adducts of all these compounds with hCA II were
reported,256,257,259−261,263 showing that these molecules bind to
hCA II active site coordinating to the Zn2+ ion by means of the
deprotonated NH− moiety of the sulfamate group (Figure 39).
The steroid ring system of 111 and 113−115 and the tricyclic
ring structure of 112 are rather well superposable, when bound
to the enzyme active site (Figure 40), with the steroidal
backbone of 113 and 115 rotated of 180° with respect to the
others, as a consequence of the presence of the 2-substituent.
All these scaffolds lie in the hydrophobic part of the active site,
establishing a large number of strong van der Waals interactions
(Figure 39A,B,C,D,E). Compound 114 makes an additional
hydrogen bond interaction between the nitrogen atom of the
pyridine moiety and residue Gln136 (Figure 39D). A
completely different orientation was observed for compounds
116−118 (Figure 39F,G,H and Figure 41). Indeed, these
molecules bind to the Zn2+ ion with the sulfamate group in
position 17 and not that in position 3 as observed for 111 and
113−115. The steroid skeletons of inhibitors 116 and 117
overlap very well, as expected from their structural similarity,
while 118 presents small differences in the angles of its ring
system compared to the other two derivatives.
The comparison of the inhibition properties of all these
compounds and the analysis of their crystal structures allowed
to derive several important features on their binding behavior.
Thus, compounds having only one sulfamate group on the
benzene ring without any substituent in position 2, such as 111,
112, and 114, were the most effective CAIs (IC50 in the range
0.1−56 nM).261,263 The presence of a substituent in position 2
reduced considerably the affinity, as observed for 113 and 115
(IC50 = 1500 and 2113 nM, respectively).
260,263 The
introduction of a second sulfamate group in position 17 (116
and 117) led to compounds with a good inhibitory action (IC50
= 662 and 169 nM, respectively).259,263 In these cases, although
the ionization of the sulfamate in position 17 is unfavorable
with respect to that of the sulfamate in position 3, the 2-
substituent could make more difficult the interaction of the 3-
O-sulfamate group with the zinc ion, due to a steric
hindrance.259 Finally, when the inhibitor contains only the
sulfamate group in position 17 (118), the efficacy decreases
(IC50 = 770 nM) with respect to the corresponding bis-
sulfamates.263 The higher inhibitory activity of bis-sulfamates
might be due to the capability of both sulfamate groups to
coordinate to the Zn2+ ion, but in the X-ray structures discussed
here only one complex was observed.259,263
An alternative approach for the treatment of the hormone-
dependent tumors consists of reducing levels of estrogens using
aromatase inhibitors. Such molecules contain as active
pharmacophore a heme-chelating azole ring, such as triazole.258
Since aromatase inhibitors given in conjunction with STS
inhibitors could maximize estrogen depletion in the treated
patients, new hybrid drugs able to inhibit simultaneously both
enzymes have been designed, originating in dual aromatase-
steroid sulfatase inhibitors (DASIs). The first examples of
DASIs are represented by compounds such as 4-[(4-O-
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sulfamoylbenzyl)(4-cyanophenyl)amino]-4H-[1,2,4]triazole
119 and 4-[(3-bromo-4-O-sulfamoylbenzyl)-(4-cyanophenyl)-
amino]-4H-[1,2,4]triazole 120.271 As already observed for the
aforementioned STS inhibitors, these molecules, containing
Figure 39. Schematic view of hCA II active site in complex with: (A) 111 (PDB file was kindly provided by Claudiu Supuran), (B) 112 (PDB code
1TTM), (C) 113 (PDB code 3BET), (D) 114 (PDB code 3C7P), (E) 115 (PDB code 2X7U), (F) 116 (PDB code 2GD8), (G) 117 (PDB code
2X7T), and (H) 118 (PDB code 2X7S).
Figure 40. Superposition of hCA II/inhibitor adducts: 111 is reported
in magenta, 112 in blue, 113 in cyan, 114 in yellow, and 115 in red.
On the right side the enlarged view of 111 and 113 inhibitors within
hCA II active site shows the different orientation of their backbone.
Figure 41. Structural superposition of hCA II/inhibitor complexes:
111 is shown in magenta, 116 in yellow, 117 in blue, and 118 red. On
the right side the zoom of 111 and 116 inhibitors within hCA II active
site shows the different orientation of their backbone.
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also a sulfamate functionality, are able to bind the CA II active
site. In particular, 119 showed an IC50 value of 27 nM against
CA II, while 120 was 4−5 times less potent, with an IC50 value
of 137 nM.258 A detailed description of the molecular
interactions between these DASIs and CA II was provided by
resolving the crystal structures of the corresponding com-
plexes.258 In particular, both molecules were located within the
active site cavity coordinating the zinc catalytic ion and
stabilized by van der Waals interactions with several protein
residues. The binding of these compounds to the enzyme was
fairly similar, but not identical. In particular, the introduction of
the bromine in compound 120 caused the rotation of the
sulfamate-bearing aromatic ring by about 30°, due to a steric
hindrance between the protein and the bulky bromine atom
(Figure 42). Thus, the positioning of the sulfamate containing
aromatic ring and accommodation of the large bromine atom
appeared to be the major factors that resulted in a significantly
lower affinity of 120 toward the CA II. More recently a new
class of DASIs, based on a biphenyl template, has been
reported, with one of the most potent compound being 3-
chloro-2′-cyano-5′-(1H-1,2,4-triazol-1-ylmethyl)biphenyl-4-yl-
sulfamate 121.262,263 As already observed for 119 and 120, this
compound, bearing a sulfamate group, is able to bind the hCA
II (IC50 value of 86 nM). The X-ray crystal structure of the
hCAII/121 adduct was solved, showing the biphenyl moiety
located at the center of active site cavity and the triazole ring
pointing toward a small cavity positioned close to the entrance
of the active site, and delimited by Leu60, Asn62, and Glu69262
(Figure 43).
In summary, the analysis of the structures of the hCA II-
sulfamates complexes confirmed that even small modifications
to the inhibitor structures can induce large modifications in the
binding mode and affinity for the various CA isoforms. Thus,
the knowledge of the interactions between sulfamate-based
ligands and hCA II could allow to support more rational drug
design strategies.
4.6. Sulfonamides/Sulfamates/Sulfamides Containing
Sugar Moieties
Among the different strategies so far developed for designing
selective CAIs, the “sugar approach” represents one of the most
interesting and versatile tools. This approach, which has led to
the development of numerous potent inhibitors of potential
clinical use,272−274 consists in the incorporation of glycosyl
moieties into different CAI scaffolds. CAIs obtained with this
approach can be schematically grouped in two major classes:
the first class contains compounds where the carbohydrate
moiety is directly attached to the sulfonamide/sulfamide/
sulfamate group (see compounds 122−127), while the second
class is characterized by molecules where the carbohydrate
moiety is attached to the organic scaffold of aromatic
sulfonamides (see compounds 128−130).273,275−278
Figure 42. Structural superposition of 119 (orange) (PDB code
1XPZ) and 120 (blue) (PDB code 1XQ0) when bound to the hCA II
active site.
Figure 43. Active site view of hCA II/121 adduct (PDB code 2WD3).
The enzyme is represented as ribbon diagram in gray.
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The marketed antiepileptic drug topiramate 122 and its
analogues 123 and 124 are interesting examples of compounds
belonging to the first class. Topiramate, 2,3,4,5-di-O-isopropy-
lidene-β-D-fructopyranose sulfamate, presents a very peculiar
chemical structure, consisting of a monosaccharide moiety
bearing a sulfamate functional group. This drug possesses
potent anticonvulsant effects, which can be ascribed to a
multifactorial mechanism of action: blockade of sodium
channels and kainate/AMPA receptors, CO2 retention
secondary to inhibition of the red cell and brain CAs, as well
as enhancement of GABA-ergic transmission.279−284 It was also
recently demonstrated that topiramate is able to induce weight
loss in obese epilepsy patients after pharmacological treat-
ment.285 Since the use of other CAIs was also associated with
weight loss,204 it was supposed that the antiobesity properties
of 122 could be due to the inhibition of the CAs involved in the
biosynthesis of lipids. According to this hypothesis, topiramate
was demonstrated to act as very potent inhibitor of several CA
isozymes, among which hCA II (KI = 13.8 nM) and hCA VA
(KI = 25.4 nM).
286,287 The structural determinants responsible
of the high affinity of 122 for these CAs were investigated by
means of a combined structural and theoretical approach.286,287
In particular, the X-ray crystal structure of the hCA II/122
complex was solved286 and used as template for a homology
modeling study on the adduct that 122 forms with hCA VA.287
The main protein-inhibitor interactions observed in these
complexes are schematically depicted in Figure 44. These
studies highlighted that whereas the sulfamate group of the
inhibitor binds to the active site of both enzymes in a similar
manner, a different network of polar interactions of the sugar
scaffold distinguishes the hCA VA/122 adduct from the hCA
II/122 one. These differences can justify the diverse binding
affinities of 122 toward the two CA isozymes,287 and offer
interesting perspectives for the design of antiobesity CAIs using
topiramate as lead compound.
Compound 123,288 the sulfamide analogue of 122 from
which differs only for the substitution of an oxygen atom with a
NH moiety, is a much less potent hCA II inhibitor. The analysis
of its crystal structure in complex with hCA II correlates well
with this finding288 Indeed, although 123 binds to the CA II
active site in a conformation very similar to that of the
sulfamate analogue, one of its methyl groups makes a clash with
the methyl side chain of Ala65,288 thus accounting for the 2
orders of magnitude lower affinity toward the enzyme.
Compound 124289 is another structural analogue of topiramate,
where one of the di-isopropylidene moieties was substituted by
a cyclic sulfate group. The X-ray structure of the hCA II/124
complex has also been reported,290 showing that this inhibitor
binds to the enzyme active site in a completely different way as
compared to 122 and 123. In particular, while the sulfamate/
sulfamide groups of these three inhibitors are well super-
posable, the sugar moiety of 124 is rotated by about 180° with
respect to those of 122 and 123 (Figure 45). This rotation is
responsible for a different pattern of hydrogen bond
interactions within the enzyme active site and consequently
for a diverse inhibition profile of the three compounds toward
hCA II (and other CA isoforms).288,289 Altogether these
findings highlighted again that even minor structural differences
in these sugar moieties can be responsible for very different
binding modes to the CA active site and consequently for very
different inhibitory effects.
Recently, several other examples of sugar derivatives
belonging to the same class as 122−124 have been reported291
(see as examples compounds 125−127). These molecules,
synthesized starting from per-O-acetylated sugar moieties,292
Figure 44. Schematic active site representation of (A) hCA II/122
crystal structure (PDB code 3HKU) and (B) hCA VA/122 adduct
obtained by a homology modeling study.
Figure 45. Structural superposition between hCA II/122 (yellow,
PDB code 3HKU), hCA II/123 (blue, PDB code 2H15), and hCA II/
124 (red, PDB code 1EOU) adducts.
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contain a primary sulfonamide group directly attached to the
anomeric center of a mono- or disaccharide fragment. In terms
of chemical structure, these compounds represent an unrelated
CAI class, since to date, no other inhibitors containing a
methine sulfonamide moiety (RR′CH−SO2NH2) have been
reported. Moreover, the observation that these compounds
presented very poor passive membrane permeability291 made
them interesting alternatives to the classical aromatic CAIs, also
offering attractive perspectives for the design of inhibitors able
to target only extracellular CA isoforms. Unfortunately, kinetic
studies on these molecules did not fulfill the expectations,
demonstrating both that they were only moderate CAIs, with
KIs in the micromolar range, and that they possessed a very flat
inhibition profile across all CA isozymes investigated.291 This
result was quite surprising especially compared to what
observed both for the classical CAIs and for the structural
related analogue topiramate, which instead presented KI values
in the low nanomolar range for several CA isoforms. Thus, a
structure-based approach was used to investigate the structural
features of these compounds responsible for their weak CA
inhibitory properties. In particular, high resolution X-ray crystal
structures were obtained for hCA II in complex with one
monosaccharide 125 and two disaccharide derivatives (the per-
O-acetylated sugar 126 and the fully deprotected sugar 127)
and compared with the X-ray structure of the hCA II/122
complex. This comparison explained well the above-reported
differences in the kinetic behavior of such compounds. Indeed,
despite the similarity in chemical structure with 122, none of
the three anomeric sulfonamides was able to form as many
direct interactions with protein residues as topiramate.291 This
finding is clearly related to the inhibitor overall shapes. Indeed
topiramate shows a peculiar “T” shape, with the sugar scaffold
spanning the diameter of the active site about 5 Å above the
catalytic zinc ion. On the contrary, the anomeric sulfonamides
present an elongated shape, resulting in less bulky inhibitors
which are not able to efficiently interact with active site residues
(Figure 46).291 These data suggest that further chemical
modifications have to be introduced into the carbohydrate
skeleton of the anomeric sulfonamides, to optimize the
protein/inhibitor binding and enhance the enzyme inhibition
activity.
The derivatization of 4-carboxy-benzenesulfonamide 12 or
sulfanilamide 5 with tails incorporating different sugar moieties
led to compounds of type 128−130 belonging to the second
class of sugar containing CAIs (see above). These compounds
were developed within a general research project aimed at
developing CAIs with applications as antiglaucoma agents. In
agreement with the design hypothesis, these molecules showed
very good CA II inhibitory activity,272−274,276 and possessed
interesting physicochemical properties, such as water solubility,
good penetrability through the cornea, etc., that made them
good candidates as topically acting antiglaucoma drugs to be
administered directly into the eye.275
One of the most promising compound of this series was N-
(4-sulfamoylphenyl)-α-D-glucopyranosylamine (glucose deriva-
tive 130). Indeed, this molecule was shown to be a potent
inhibitor of several CA isozymes and a promising antiglaucoma
agent with topical activity in an animal model of the disease.276
The crystallographic structure of 130 in complex with hCA II
was also solved providing insights into the molecular basis of its
strong enzyme inhibitory activity.278 In particular, while the
sulfonamide and the phenyl ring of the inhibitor bound in the
canonical way to the enzyme, the glycosyl moiety, responsible
for the high water solubility of the compound, was oriented
toward the hydrophilic region of the active site, stabilized by a
network of hydrogen bonds with five water molecules and the
Figure 46. View of the shape complementarities between hCA II active site and (A) 122 (PDB code 3HKU), (B) 125 (PDB code 3HKQ), (C) 126
(PDB code 3HKN), and (D) 127 (PDB code 3HKT). The inhibitor atoms are shown as spheres and the enzyme is represented as a surface-model.
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enzyme residues Gln92 and Pro201 (Figure 47).278 It is
interesting to observe that the type of interactions observed in
the hCAII/130 adduct was completely different from those
reported for the other sugar derivatives reported above and thus
this could be suitably used for the rational drug design of other
sugar-based CAIs.
5. INSIGHTS INTO CA INHIBITION: STRUCTURAL
FEATURES OF NON-ZINC-BINDING INHIBITORS
An increasing number of different chemotypes than the
sulfonamides and their isosteres has been recently reported to
act as CAIs. Among them are the phenols293−295 (some of
which are natural compounds),296 the polyamines,297 the
coumarins,298,299 and the antiepileptic drug lacosamide.300
Interestingly, all these type of derivatives, differently from
sulfonamides and their isosteres, bind to the CA active site not
interacting directly with the catalytic zinc ion. In particular,
phenols295,296 and polyamines297 are anchored to the zinc-
coordinated water molecule/hydroxide ion, whereas the
recently reported class of effective and in some cases isoform-
selective CAIs, the coumarins and thiocoumarins,298,299 binds
(in hydrolyzed form) far away from the zinc ion, not interacting
at all with it, partially occluding the entrance to the active site.
The antiepileptic lacosamide300 binds similarly to the hydro-
lyzed coumarins, although it bears no chemical similarity at all
with them. The main structural features of all these classes of
inhibitors will be summarized in the next paragraphs.
5.1. Compounds Anchoring to the Zinc Bound Water
Molecule
5.1.1. Phenols. Phenols constitute a class of compounds
which over the years have had different applications as
pharmacological agents in the treatment of a wide variety of
diseases. Indeed, they have been reported to possess anticancer,
antioxidant, antimutagenic, antibacterial, antiviral or anti-
inflammatory activities.301−312
The simplest member of this family of compounds is phenol
131, which as far as in 1982 was discovered to be a competitive
inhibitor of human CA II by Lindskog’s group.293,294
Subsequently, the X-ray crystal structure of its adduct with
hCA II was solved, providing structural reasons of such a
kinetic behavior.295 In particular, the analysis of the structure
revealed the binding of two 131 molecules to the enzyme. The
first one was located in a hydrophobic patch about 15 Å away
from the catalytic zinc ion and close to a symmetry-related
molecule.295 However, since this location does not correspond
either to the molecular trajectory of CO2 or secondary CO2
binding sites predicted in molecular dynamics calculation-
s,79,313it is likely that this binding does not interfere with CA II
catalytic activity. A second phenol molecule was found within
the active site, showing a completely new binding mode.
Indeed, this molecule did not coordinate to the zinc ion, but
was anchored to the active site through two hydrogen bonds of
the OH moiety with the zinc-bound water/hydroxide ion and
the NH amide of Thr199 (Figure 48). Furthermore, the
aromatic ring was found to lie in a hydrophobic pocket of the
active site, delimited by residues Val121, Val143, Leu198, and
Trp209 (Figure 48). These findings, together with the
observation that 131 was a competitive CA II inhibitor,
provided the first evidence, very recently confirmed by two
independent structural studies,69,70 that the hydrophobic
pocket delimited by Val121, Val143, Leu198, and Trp209
constitutes the CO2 binding pocket. It is worth noting that this
crystal structure represented the first direct evidence that
phenol binds to the enzyme without altering the coordination
of the zinc ion, confirming the results obtained indirectly by
previous spectroscopic studies of Co(II)-substituted CA II and
its phenol complex,293 and by molecular modeling studies
based on 13C NMR data.314
Figure 47. Representation of the active site in the hCA II/130
complex (PDB code 2HL4) showing residues participating in
recognition of the inhibitor molecule. Hydrogen bonds and the active
site Zn2+ coordination are also shown. Water molecules are shown as
red circles.
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More recently, additional structural information on the
binding mode of phenolic derivatives to the CA active site has
been obtained. In particular, xylariamide A 132, a phenolic
natural product, which acts as micromolar hCA II inhibitor (KI
= 8 μM) and possesses a methyl ester moiety, has been
cocrystallized with hCA II.296 The main hCA II/132
interactions, as derived from the analysis of this structure, are
shown in Figure 49. Surprisingly, differently from 131,
compound 132 is anchored to the zinc bound water molecule,
not through the OH phenolic moiety but by means of a
hydrogen bond involving the carbonyl oxygen of the ester
functionality, which also makes a second hydrogen bond with
the Thr199NH atom. The methyl moiety of the ester
functionality is in van der Waals contact with Trp209. Various
oxygen/nitrogen atoms of the inhibitor make additional direct
or solvent-mediated hydrogen bonds with several enzyme
residues, such as Thr200, Gln92, Pro201, and Asn62, whereas
the chlorophenol moiety was slightly disordered (two
conformations were observed), making only van der Waals
contacts with CA II active site. These data, together with
several recently reported inhibition studies against all α-CA
isozymes on synthetic or natural phenolic products,315−319
strongly suggest that phenol 131 represents a lead compound
that can be utilized to obtain novel CAIs, different from
classical sulfonamides and their isosteres. In particular, different
substitution patterns of such lead can be used to significantly
modulate the binding mode and consequently affinity and
selectivity toward different CAs.
5.1.2. Spermine and Related Polyamines. Several
kinetic and X-ray crystallographic studies demonstrated that
amines such as histamine or L-adrenaline were able to
effectively activate many CA isoforms.320−331 Indeed, these
molecules were shown to bind at the entrance of the CA active
site facilitating, through their protonatable groups, the rate
limiting step of the catalytic cycle: the deprotonation of the
Zn2+ bound water molecule with the formation of the zinc
hydroxide species of the enzyme (see Introduction).70,72−75 On
the basis of these observations it was suggested that
polyamines, such as spermine 133, spermidine 134, N,N′-bis-
(3-aminoethyl)-1,3-propanediamine 135 and triethylenetetr-
amine 136, could also act as CA activators, since they possessed
3−4 primary/secondary amine groups in their molecules, with
pKas in the range 7.9−10.9. Surprisingly, recently reported
kinetic studies demonstrated that these molecules did not have
at all activating properties against hCA isoforms, but on the
contrary showed significant inhibitory features.297 Moreover,
each of these polyamines showed a diverse inhibition profile
against different CA isozymes, probably reflecting several
factors controlling activity, such as the length of the aliphatic
chain of the polyamine, the number of amine functionalities
present in it, and presumably the charged character (as
ammonium cations) of these molecules. Indeed, the different
12 catalytically active isoforms were inhibited with potencies
ranging from the low nanomolar to the millimolar range by 133
and 134, whereas the synthetic compounds 135 and 136
showed weaker inhibition, with affinities in the micro−
millimolar range (Table 5).
To better understand the inhibitory mechanism of this new
class of CAIs, the X-ray crystal structure of spermine 133 in
adduct with hCA II was solved.297 The main protein-inhibitor
interactions observed in this structure are schematically
depicted in Figure 50. According to this figure, the polyamine
133, which in the experimental conditions used is probably a
tetracation, adopts a coiled conformation when bound to the
enzyme active site. It was found bound deep within the hCA II
active site, but interestingly it was not directly coordinated to
Figure 48. Schematic representation of the binding mode of 131 to
the hCA II active site. Zn2+ coordination, polar and hydrophobic
interactions (distance < 4.5 Å) are also reported.
Figure 49. Active site view of hCA II/132 adduct (PDB code 3P4V)
showing residues participating in recognition of the inhibitor molecule.
Only one conformation of the chlorophenol moiety is reported. Water
molecules are shown as red circles.
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the metal ion. In particular, the polyamine was anchored to the
Zn2+ bound hydroxide ion by means of a strong hydrogen bond
involving one of its terminal ammonium groups, in a way
reminiscent of the binding of phenol 131.295 The same moiety
participates in a second hydrogen bond with the Thr199OG1
atom. Additional hydrogen bonds with residues Thr200 and
Pro201 and several van der Waals contacts with enzyme
residues Gln92, Val121, Phe131, Val143, Leu198, Thr199,
Thr200, Pro201, and Pro202 further stabilize the adduct
(Figure 50). The analysis of this structure clearly shows that
spermine binds within the CA active site in a completely
different way than classical sulfonamides, justifying the peculiar
inhibition profile of this class of new CAIs. These findings open
the way to the development of a new class of CAIs with a
diverse inhibition mechanism, and hopefully a diverse
selectivity profile for various CA isoforms (for example,
spermine is a CA IV-selective inhibitor, with binding costants
to this isoform in the low nanomolar range, whereas for other
ones it binds in the micro- or millimolar range) (Table 5).297
5.2. Compounds Located at the Entrance of the Active Site:
Coumarins and Lacosamide
In the continuous search of novel chemotypes which could act
as efficient CAIs, Vu and co-workers332 recently reported an
elegant study where ESI-FTICR-MS techniques were used for
the screening of a large number of natural product extracts
against bCA II. To the general surprise, this approach led to the
identification of a natural product, namely 6-(1S-hydroxy-3-
methylbutyl)-7-methoxy-2H-chromen-2-one 137, as CA II
inhibitor. This result was of a great interest since compound
137 is a coumarin with a chemical structure completely
different from all other CAIs investigated earlier, thus
constituting a putative valuable lead for the design of new
CAIs. Starting from these observations it was evidently
necessary to investigate coumarins as a new class of CAIs.
For this aim, Supuran’s group recently reported a detailed
inhibition study of compound 137, and many structurally
related analogues, among which 138 and 139, against all
catalytically active CAs,298 providing a series of very interesting
observations. In particular, these studies showed that when an
incubation time of 10−15 min was allowed for the formation of
the enzyme−inhibitor adduct, as generally done for other types
of CAIs, only a weak micromolar to millimolar inhibition was
observed; on the contrary, more effective inhibitory properties
were observed using higher incubation times (6 h) (see Table
6).298 Indeed, in these conditions coumarins 137−139 were
shown to inhibit all the investigated CA isoforms, with
inhibition constants ranging from nanomolar to millimolar.
To understand this peculiar inhibition profile, the two
coumarins 137 and 138 were cocrystallized with hCA
II.298,299 Surprisingly, the analysis of the electron density
maps in both complexes did not show the binding of such
compounds in the enzyme active site, but evidenced the
binding of their hydrolysis products, namely the cis-2-hydroxy-
Table 5. Inhibition Data of Polyamines 133−136 against CA
Isozymes I−XIV by a Stopped-Flow CO2 Hydration Assay
Methoda
KI (μM)
isozymeb 133 134 135 136
hCA Ic 231 1.40 115 100
hCA IIc 84 1.11 75 64
hCA IIIc 167 11.5 63 48
hCA IVc 0.010 0.112 44 35
hCA VAc 0.84 1.22 50 38
hCA VBc 0.83 1.44 59 49
hCA VIc 0.99 1.41 53 43
hCA VIIc 0.71 1.23 58 45
hCA IXd 13.3 1.37 48 39
hCA XIId 27.6 44.1 68 57
mCA XIIIc 22.6 11.6 66 52
hCA XIVc 0.86 1.00 36 12.1
aData were obtained by ref 297. bh = human, m = murine isozyme.
cFull length enzyme. dCatalytic domain.
Figure 50. Representation of the active site of the hCA II/133
complex (PDB code 3KWA) showing residues participating in
recognition of the inhibitor molecule.
Table 6. Inhibition Data of Mammalian Isozymes CA I-XIV
with Coumarins 137−139 by a Stopped-Flow CO2
Hydration Assay Methoda
KI (μM)
isozymeb 137e 138e 139e
hCA Ic 0.08 3.1 5.9
hCA IIc 0.06 9.2 0.07
hCA IIIc >1000 >1000 161
hCA IVc 3.8 62.3 7.8
hCA VAc 96.0 >1000 645
hCA VBc 17.7 578 48.6
hCA VIc 35.7 >1000 61.2
hCA VIIc 27.9 >1000 9.1
hCA IXd 54.5 >1000 767
hCA XIId 48.6 >1000 167.4
mCA XIIIc 7.9 >1000 6.0
hCA XIVc 7.8 >1000 9.7
aData were obtained by ref 298. bh = human, m = murine isozyme.
cFull length enzyme. dCatalytic domain. ePreincubation of 6 h
between enzyme and inhibitor.
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4-(1S-3-methylbutyl)-3-methoxy-cinnamic acid 140 and trans-
2-hydroxy-cinnamic acid 141, for 137 and 138, respectively, to
the CA II active site. These data were explained assuming that
the zinc-bound hydroxide anion, responsible for the various
catalytic activities of CAs,1,2,5 among which the esterase
activity,333 hydrolyzes the lactone ring of 137 and 138 leading
to the formation of the corresponding 2-hydroxy-cinnamic
acids (see Scheme 4). The obtained hydrolysis products did not
leave the active site but remained bound to its entrance,
partially occluding it, stabilized by a large number of
hydrophobic and polar interactions (Figure 51). This suicide
inhibition mechanism was then confirmed by several kinetic
and mass spectrometry experiments.298
Altogether these data showed that coumarins constitute a
totally new class of CAIs, with a novel inhibition mechanism.
The unusual binding mode of these compounds makes their
scaffolds a very promising starting point to develop nonclassical
CAIs with more isoform selectivity. In particular, as coumarins
bind to the entrance of the active site cavity, which is the region
with a minor number of conserved residues among the different
CAs, this binding mode offers the possibility to design
inhibitors with improved selectivity with respect to the already
existing CAIs. Indeed, several studies334,335 evidenced a rather
large number of coumarin derivatives possessing CA IX, CA
XII, CA XIII, and other CA isoform-selective behavior. Of great
importance is the discovery of highly selective CA IX/XII
inhibitors belonging to the coumarin class, which do not
significantly inhibit CA I and II.334,335 One such compound, a
glycosyl-substituted coumarin, showed excellent antitumor and
antimetastatic effects in an animal model of breast cancer and
has been further evaluated in preclinical models of this
disease.336
(2R)-2-Acetylamino-N-benzyl-3-methoxypropionamide 142
(known as lacosamide) is an antiepileptic drug (discovered
by Kohn’s group),337−343 which possesses some analogies with
coumarins when binding to the CA II active site. Indeed, a
recently reported inhibition study showed that lacosamide
inhibits mammalian CAs I-XV with inhibition constants in
range of 331 nM to 4.56 μM.300 Moreover, its crystallographic
structure in complex with CA II reveals that lacosamide binds
to CA II, being located in the same site where coumarins were
found (Figure 52), making favorable van der Waals interactions
with Ile91, Gln92, Val121, Phe131, and Leu198. Again, as
observed for coumarins no interactions with the Zn2+ catalytic
Scheme 4. CA-Catalyzed Hydrolysis of Coumarins 137 and
138 to the Corresponding 2-Hydroxy-cinnamic acids 140
and 141
Figure 51. Solvent accessible surface of hCA II/140 adduct (PDB
code 3F8E) showing the inhibitor position at the entrance of the
enzyme active site.
Figure 52. Superposition of hCA II/inhibitor adducts: 140 is reported
in blue and 142 (PDB code 3IEO) in red. Zn2+ coordination is also
shown. hCA II is represented as ribbon diagram.
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ion were evidenced.300 Such findings indicate that the
coumarin-binding site may accommodate structurally diverse
compounds which possess an inhibition mechanism distinct of
that of sulfonamides, opening new perspectives for designing
new CAIs with various biomedical applications.
6. CONCLUSIONS
A large amount of X-ray structural data have been accumulated
in the last years for adducts of CAs with the main classes of
inhibitors: the pharmacologically relevant sulfonamides and
their isosteres (sulfamates and sulfamides), ureates and
hydroxamates, the simple inorganic anions, phenols, poly-
amines, and very recently, the totally new class of inhibitors, the
coumarins/thiocoumarins. However, although X-ray crystal
structures are already available for the majority of the twelve
catalytically active members of the human CA family, most of
the reported complexes involves isozyme II. A careful analysis
of these data allowed to divide CA inhibitors in two main
classes: those that bind the enzyme active site anchoring
themselves to the catalytic zinc ion, and those that are bound in
the active site but do not interact directly with the metal ion.
The inhibitors belonging to the first class, the most studied
ones from a structural point of view, are generally characterized
by three main structural elements: a ZBG, an organic scaffold,
and one or more “tails”. The ZBGs leading to very potent CAIs
may belong to various functionalities, with the classical
sulfonamide one still constituting the main player. However,
bioisosteres of the SO2NH2 moiety, such as the sulfamate and
sulfamide groups, were shown to lead to inhibitors equipotent,
and in some cases even stronger than the corresponding
sulfonamides. Several others ZBGs, such as unsubstituted
hydroxamates, N-hydroxy-urea and urea, have also been
explored in detail by means of crystallographic methods and
can be considered as promising alternatives.
A large number of organic scaffolds were also investigated,
with four main groups of compounds evidenced so far:
aromatic, heterocyclic, aliphatic and sugar derivatives. Aromatic
(most of the time benzene or naphthalene derivatives)
sulfonamides constitute by far the most extensively investigated
class of CAIs. The heterocyclic sulfonamides are immediately
second in importance to the benzenesulfonamides, considering
the fact that they are contained in many of the clinically used
CA inhibitors. Many of these CAIs incorporate 5-membered
sulfur-containing heterocycles (thiophene, 1,3,4-thiadiazole,
1,3,4-thiadiazoline) or annulated 5-membered such rings
(benzo-[b]-thiophene, benzo-thiazine, etc.). Several aliphatic
derivatives were also investigated, such as the clinically used
antiepileptic zonisamide, and some 1,3,4-thiadiazole derivatives
substituted with CH2SO2NH2 or CF2SO2NH2 moieties. The
binding modes and selectivity profiles for inhibition of
mammalian CAs by these compounds are totally new and
different from those of the aromatic/heterocyclic sulfonamides
investigated earlier. Thus, more detailed investigations of the
aliphatic derivatives as CAIs, eventually incorporating other
ZBGs than the sulfonamide one, are highly desirable and may
lead to important advances. Finally several sugar derivatives,
incorporating both sulfonamide, sulfamate and sulfamide ZBGs,
were also characterized by means of X-ray crystallography,
leading to very interesting results.
However, the main problem with CAIs incorporating only
the ZBG and the organic scaffold, was related to the fact that
they were promiscuous inhibitors of all (or most of the) hCAs,
since the interactions of the ZBGs and the organic scaffold with
the enzyme were basically the same between the inhibitors and
most CA isozymes. For this reason in 1999 Supuran’s group
developed the so-called “tail-approach”, which afforded the
rather simple synthesis of a large number of CAIs starting from
aromatic/heterocyclic scaffolds. In this approach various
moieties (tails) were introduced by normal chemical
modification reactions (acylation, alkylation, arylsulfonylation,
condensation, etc.) in the aromatic/heterocyclic scaffold. In this
way, it was possible both to modulate the physicochemical
properties of the synthesized inhibitors, such as water solubility,
lipophilicity, membrane impermeability etc., and their affinity to
the various isozymes. These novel generation inhibitors showed
much more interesting inhibition profiles as compared to the
classical ones. Both X-ray crystal structures with isoform II and
homology models with other relevant isoforms are available for
some of these compounds, proving that both favorable
interactions as well as clashes with particular amino acids, are
critical for the inhibition profile and isozyme selectivity issues.
The main problem with this type of inhibitors resides in the
predominant role played by the ZBG in the interaction with CA
active site. As a consequence, any change in the thermody-
namics of binding caused by the nature of the organic scaffold
and/or the tail may have only a small effect on the enzyme−
inhibitor affinity, and consequently requires a very careful
experimental design. For this reason, the last years have seen
the development of the second class of inhibitors, among which
phenols,295,296 polyamines,297 coumarins/thiocoumarins, and
the antiepileptic drug lacosamide298,299 are the most interesting
examples. These molecules are bound in the active site but do
not interact directly with the catalytic zinc ion. In particular,
phenols and polyamines are anchored to the zinc-coordinated
water molecule/hydroxide ion, while the coumarins and
lacosamide bind to the border of the active cavity partially
occluding its entrance. Thus, over the years, starting from the
zinc binders, novel generations of inhibitors were observed to
bind further and further away from the zinc. This is of great
interest since the regions of the active site, which are less
conserved among the different isoforms are those at the
entrance of the cavity. This also explains why inhibitors which
bind to these regions show much better degrees of isoform
selectivity, and often inhibit strongly only one, or a restricted
number of isoforms, among the fifteen presently described in
humans.
Altogether these studies have demonstrated that, even
though much work must be still done, important progresses
on the knowledge of factors governing selective inhibition have
been obtained. Indeed, some examples of isozyme-specific
inhibitors are already available and are described in the
concluding part of this review.
Spermine297 133 is a polyamine which behaves as a CA IV-
highly selective inhibitor. In fact, it is a low nanomolar inhibitor
only of CA IV (KI of 10 nM) whereas its inhibition of other
isoforms is in the micromolar range.297 As the physiological
role of CA IV in many tissues is not known exactly, spermine
and some of its congeners may constitute important tools to
unravel the precise function of this extracellular isoform.
Recently two different examples of CA VA/VB-selective
inhibitors have also been reported. The first example is
constituted by some naturally occurring phenols of types 132
and 143−147, which show nanomolar inhibition of the
isoforms hCA VA and VB, and only micromolar affinity for
the offtarget one hCA I and II.344,345 The second example is
represented by a class of highly lipophilic sulfonamides
Chemical Reviews Review
dx.doi.org/10.1021/cr200176r | Chem. Rev. 2012, 112, 4421−44684459
incorporating R- or S-camphorsulfonyl moieties.346 Indeed
some of these derivatives, such as 148, show the following
inhibition constants: KI (CA I) = 5246 nM, KI (CA II) = 1773
nM, KI (CA VA) = 5.9 nM, and KI (CA VB) = 7.8 nM.
346 This
is the most mitochondrial isoform-selective sulfonamide CAI
reported to date.
A series of low nanomolar and subnanomolar CA VI
inhibitors was also reported,347 belonging to the glycosyl-
amine−sulfanilamide class of which compound 130 is an
example. The glucose, ribose, arabinose, xylose, and fucose
derivatives show excellent CA VI inhibitory activity, with KIs in
the range of 0.56−5.1 nM, whereas the least active derivatives,
incorporating gallactose, mannose, and rhamnose scaffolds have
inhibition constants in the range of 10.1−34.1 nM. Many of
these sulfonamides are also selective inhibitors for their
interaction with CA VI over the physiologically dominant and
ubiquitous isoform CA II, with selectivity ratios of 4.11−35.93
for inhibiting the secreted over the cytosolic isozyme. Because
of their high water solubility and high affinity for CA VI over
CA II, these compounds might be useful tools for better
understanding the secreted isoform CA VI.
The first series of CA VII-selective sulfonamide CAIs was
reported by Guzel et al.348 Indeed, derivatives of types 149−
152, incorporating aromatic or heterocyclic sulfonamide heads
and the aryl-CH2CONH moieties show low nanomolar
inhibitory activity against hCA VII (KIs in the range of 4.7−
8.5 nM, and selectivity ratios for inhibiting CA VII over CA II
in the range of 8.6−49.6). Thus, the advent of such CA VII-
selective inhibitors has opened the possibility of being able to
establish soon the involvement of CA VII both in epilepto-
genesis and neuropathic pains.349
Important results have been obtained also with isozymes CA
IX and XII, which, as described in the Introduction, are
predominantly found in tumor cells. Several approaches have
been reported in the last years for obtaining compounds that
specifically target such isoforms among which: (i) fluorescent
sulfonamides (such as compounds 42 discussed in this review),
used for imaging purposes and for determining the role of CA
IX in tumor acidification;151 (ii) positively (such as compounds
29−31 discussed in the review) or negatively charged
compounds, which cannot cross plasma membranes due to
their charged character and thus inhibit selectively only
extracellular CAs, among which CA IX and XII;150 (iii)
hypoxia-activatable compounds, which exploit the reducing
conditions of hypoxic tumors to convert an inactive prodrug
into an active inhibitor;185 (iv) sugar-containing sulfonamides/
sulfamates/sulfamides, which due to their highly hydrophilic
character do not easily cross membranes and thus possess an
enhanced affinity for extracellular CAs;275 (v) nanoparticles
coated with CAIs.162
However, the most important perspectives in the drug design
of CA IX selective inhibitors stemmed only recently from the
crystal structure resolution of the enzyme catalytic domain,63
which highlighted two unique features of this enzyme: its
dimeric nature with both active sites exposed on the same side
of the dimer and the location of the proteoglycan-like (PG)
domain at the border of the active site cleft. Indeed, it is
imaginable that “two-prong” inhibitors, able to target at the
same time either both active sites or the active site and the PG
domain, could represent an interesting alternative to classical
CA inhibitors, which target only the active site.
Moreover, the structural comparison of CA IX with other
membrane associated CAs highlighted important differences in
the region of amino acids 125−137, located at the border of the
active site cavity, making this region an interesting target to
address in the rational drug design of selective inhibitors. These
findings are well in agreement with the observation of a good
degree of selectivity showed by the most recently reported
family of CAIs, that is, coumarins,298 which were shown to bind
at the border of the active site close to this region. In particular,
some studies, which reported a large series of derivatives
(compounds 139 and 153−162) possessing various moieties
substituting the (thio)coumarin ring,299,334,335 led to indentify
some truly CA IX-selective inhibitors. For example compound
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160c was shown to be a low nanomolar inhibitor of only CA IX
(KI of 48 nM), whereas it inhibited in the micromolar range all
other twelve CAs, a feature never evidenced before for a
sulfonamide CAI.
But the real breakthrough in the investigations of CAIs as
antitumor agents has been only very recently published.336,350
In particular, it has been reported that both sulfonamidic (such
as the ureido derivative 26) and coumarinic (such as the
glycosyl coumarin 163) CA IX inhibitors strongly inhibit the
growth of both primary tumors and metastases in several
animal models of breast cancer.336,350 These data undoubtfully
demonstrate the potential of CA IX inhibition for designing
antitumor/antimetastatic agents possessing a novel mechanism
of action with respect to the existing drugs.
Unfortunately no isoform selective compounds have been
described so far for CA XIII and CA XIV, except some
coumarins which are CA XIII-selective.334,335
But what about CA I and II? Are there isoform selective
inhibitors for them? The answer is yes, and again the coumarins
provide the best examples of CA I and II-selective compounds.
The natural product coumarin 137 was a nanomolar CA I and
II inhibitor but inhibited all other isoforms only in the high
micromolar range. The simple, unsubstituted coumarin 138 is
also a similar case, showing low micromolar inhibition of CA I
and II, and a millimolar inhibition of isoforms CA III−CA XV
(see Table 6). All these data clearly show that it may be
possible to obtain CAIs with selectivity for each of human
isoforms, although this field is very new. We conclude the
review stressing the fact that the family of CAs, with their large
number of isoforms, provides an excellent scientific example of
successful drug design of selective inhibitors for structurally
very similar proteins. With their multiple medicinal chemistry
applications, such isoform-selective compounds may lead to
novel drugs with less side effects compared to the present ones
in a wide range of diseases.
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(348) Güzel, Ö.; Innocenti, A.; Scozzafava, A.; Salman, A.; Supuran,
C. T. Bioorg. Med. Chem. Lett. 2009, 19, 3170.
(349) Asiedu, M.; Ossipov, M. H.; Kaila, K.; Price, T. J. Pain 2010,
148, 302.
(350) Pacchiano, F.; Carta, F.; McDonald, P. C.; Lou, Y.; Vullo, D.;
Scozzafava, A.; Dedhar, S.; Supuran, C. T. J. Med. Chem. 2011, 54,
1896.
Chemical Reviews Review
dx.doi.org/10.1021/cr200176r | Chem. Rev. 2012, 112, 4421−44684468
